US20220098589A1 - Composition for delivery of genetic material - Google Patents
Composition for delivery of genetic material Download PDFInfo
- Publication number
- US20220098589A1 US20220098589A1 US17/548,995 US202117548995A US2022098589A1 US 20220098589 A1 US20220098589 A1 US 20220098589A1 US 202117548995 A US202117548995 A US 202117548995A US 2022098589 A1 US2022098589 A1 US 2022098589A1
- Authority
- US
- United States
- Prior art keywords
- exosomes
- exosome
- cells
- oligonucleotide
- genetic material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 57
- 238000012384 transportation and delivery Methods 0.000 title description 37
- 239000000203 mixture Substances 0.000 title description 21
- 210000001808 exosome Anatomy 0.000 claims abstract description 233
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000030279 gene silencing Effects 0.000 claims abstract description 16
- 238000001415 gene therapy Methods 0.000 claims abstract description 12
- 238000001727 in vivo Methods 0.000 claims abstract description 11
- 238000012226 gene silencing method Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 87
- 238000001890 transfection Methods 0.000 claims description 33
- 239000013612 plasmid Substances 0.000 claims description 32
- 239000012096 transfection reagent Substances 0.000 claims description 23
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 108020004459 Small interfering RNA Proteins 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- -1 methoxy-ethyl Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000005451 thionucleotide Substances 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 230000008685 targeting Effects 0.000 description 58
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 210000004443 dendritic cell Anatomy 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 32
- 102000016911 Deoxyribonucleases Human genes 0.000 description 30
- 108010053770 Deoxyribonucleases Proteins 0.000 description 30
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 27
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 27
- 238000004520 electroporation Methods 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 21
- 108020004707 nucleic acids Proteins 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 238000011529 RT qPCR Methods 0.000 description 17
- 102000035160 transmembrane proteins Human genes 0.000 description 17
- 108091005703 transmembrane proteins Proteins 0.000 description 17
- 239000011324 bead Substances 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 230000007935 neutral effect Effects 0.000 description 15
- 238000003197 gene knockdown Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 description 13
- 101150117895 LAMP2 gene Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 108010048032 cyclophilin B Proteins 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000001476 gene delivery Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101150048357 Lamp1 gene Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002487 multivesicular body Anatomy 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000010379 pull-down assay Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 229940063675 spermine Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000047466 Syntaxin-3 Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 102000010660 flotillin Human genes 0.000 description 2
- 108060000864 flotillin Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008073 immune recognition Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940125759 BACE1 protease inhibitor Drugs 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100028927 Secretin receptor Human genes 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000014569 mints Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108700027603 secretin receptor Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Definitions
- the present invention relates to compositions for the delivery of nucleic acid or genetic material.
- the present invention relates to exosomes, loaded with genetic material and methods of producing them.
- Nucleic acids are routinely used in gene therapy for the replacement of non-functional genes [1] and for neutralization of disease-causing mutations via RNA interference (RNAi) effector molecules such as miRNAs [2], shRNAs [3] and siRNAs [4].
- RNA interference RNA interference effector molecules
- miRNAs miRNAs
- shRNAs shRNAs
- siRNAs siRNAs
- naked DNA and RNA are difficult to deliver in vivo due to rapid clearance [5], nucleases [6], lack of organ-specific distribution and low efficacy of cellular uptake, specialized gene delivery vehicles are usually used for delivery.
- Viral vectors and cationic liposomes are at the forefront of delivery vehicle technology and have been relatively successful with a large number of these delivery vehicles already in clinical trial [7]. Despite these successes, there remain significant limitations that restrict many applications, the most significant of which are immune recognition [8, 9, 10] for most viral vectors and mutagenic integration [11] for viruses such as lentiviruses; and inflammatory toxicity and rapid clearance for liposomes [12, 13, 14, 15]. Recognition by the innate immune system leads to acute inflammatory responses, which may require the use of immunosuppression strategies to overcome uptake and re-administration issues of current strategies [16, 17, 18] potentially exposing patients to unwarranted risks of opportunistic infections. Antibodies generated against the delivery vehicles also dramatically decrease transgene expression on subsequent administration [19].
- Exosomes are small membrane-bound vesicles (30-100 nm) of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Exosome production has been described for many immune cells including B cells, T cells, and dendritic cells (DCs). Exosomes derived from B lymphocytes and mature DCs express MHC-II, MHC-I, CD86 and ICAM-1 [23, 24], and have been used to induce specific anti-tumor T cytotoxic responses and anti-tumor immunity in experimental models and clinical trials [24, 25].
- exosome-mediated gene delivery has been shown with delivery of murine mRNAs and miRNAs to human mast cells [26] and glioma-derived exosomes [27] have been demonstrated to transfer mRNAs produced by exogenous DNA plasmids to heterologous cells, but loading and delivery of exogenous DNA, siRNAs and other modified oligonucleotides has not been demonstrated as yet.
- the present inventors have successfully loaded exosomes with exogenous genetic material, and in particular exogenous plasmid DNA, siRNA and modified oligonucleotides.
- the present invention relates to methods for loading exosomes with exogenous genetic material, the exosomes loaded with such exogenous genetic material, and their use in delivery of the nucleic acid for gene therapy and gene silencing.
- the present inventors have also successfully introduced targeting moieties into exosomes so that the exosomes can be targeted to a selected tissue.
- the present invention relates to exosomes which have a targeting moiety expressed on their surface and to fusion proteins comprising exosomal transmembrane proteins and a targeting moiety, and to nucleic acid constructs encoding such fusion proteins.
- the exosomes can be loaded with exogenous genetic material, and used in delivery of the nucleic acid for gene therapy and gene silencing.
- composition comprising an exosome, wherein the exosome is loaded with exogenous genetic material.
- the invention provides a composition comprising an exosome containing genetic material, wherein the exosome is derived from an immature dendritic cell, for use in a method of delivering the genetic material in vivo.
- the invention provides a method of loading exosomes with genetic material comprising providing a composition of exosomes, and loading the exosomes with genetic material by electroporation.
- the invention provides a method of loading exosomes with genetic material comprising providing a composition of exosomes and loading the exosomes with nucleic acid by transfection, using a cationic liposome transfection agent.
- composition comprising an exosome, wherein said exosome comprises a targeting moiety expressed on the surface of the exosome.
- the invention provides a polypeptide comprising an exosomal transmembrane protein, and a heterologous targeting peptide, wherein the targeting peptide binds to a moiety present on the surface of the cell to be targeted, and wherein when the polypeptide is present in an exosome, the targeting peptide is present on the surface of the exosome.
- the invention provides a polynucleotide construct encoding a polypeptide, wherein the construct comprises polynucleotide encoding a 5′ exosomal transmembrane signal sequence, for example an endoplasmic reticulum-targeting signal peptide operatively linked to polynucleotide encoding the polypeptide of the invention.
- the invention provides a method of targeting an exosome to a selected tissue or cell type comprising transfecting a host cell with a polynucleotide construct according to the invention, expressing the construct in the host cell, and obtaining exosomes from the host cell in which the construct has been expressed.
- FIGS. 1A-1C Characterization of exosomes from immature dendritic cells: FIG. 1A : Electron micrographs of exosomes stained with 2% uranyl acetate (exosomes negatively stained); FIG. 1B : Western blot of exosomes probed with anti-Lamp2, a membrane protein present in exosomes; FIG. 1C : Dynamic light scattering size measurements of purified dendritic cell exosomes in PBS from 5 different purifications
- FIG. 2C qRT-PCR of dendritic cells transfected with pLamp2b-MSP, -RVG or nothing using primers specific for MSP and RVG sequences;
- FIG. 2D Western blot with anti-Lamp1 after incubation of normal exosomes and FLAG exosomes with anti-FLAG beads or anti-AGO1 beads (non-binding control) in an exosome pulldown assay;
- FIG. 2E Dynamic light scattering size measurements of purified MSP-exosomes.
- FIGS. 4A-4C Exosome-mediated delivery of pEGFP-NAD into cells:
- FIG. 4A Transfection of Neuro2A cells with wild-type exosomes and exosomes expressing RVG-Lamp2b (RVG-exosomes) transfected with pEGFP-NAD compared to plasmid alone after DNase treatment.
- FIGS. 4B and 4C qRT-PCR quantification of fold change of eGFP after transfection with normal, RVG- or MSP-exosomes over transfection reagent alone.
- 5C and 5D qPCR of GAPDH levels in Neuro2A cells and C2C12 cells harvested 2 days after transfection with siRNA alone (siRNA), siRNA with lipofectamine 2000 (Invitrogen) (siRNA+LP), normal exosomes (Exosomes), MSP exosomes (MSP exos) and RVG exosomes (RVG exos). (*p ⁇ 0.05) Representative Western blots of GAPDH levels after similar transfections were performed (data not shown).
- FIGS. 6A-6B Knockdown of cyclophilin B with exosome-mediated siRNA delivery: FIGS. 6A and 6B : qPCR of cyclophilin B levels in Neuro2A cells and C2C12 cells harvested 2 days after transfection with siRNA alone (siRNA), siRNA with lipofectamine 2000 (Invitrogen) (siRNA+LP), normal exosomes (Exosomes), MSP exosomes (MSP exos) and RVG exosomes (RVG exos). (*p ⁇ 0.05) Representative Western blots of cyclophilin B levels after similar transfections were performed (data not shown).
- FIGS. 7A-7C Retention of Cy3 and Cy5 labeled siRNA after electroporation with exosomes:
- FIG. 7A Fluorescence correlates linearly to siRNA mass.
- FIGS. 7B and 7C Absolute mass of labeled siRNA retained after FIG. 7B , 3 ⁇ g of siRNA was electroporated with 3 ⁇ g p.e. of RVG-exosomes in 200 ⁇ l of buffer at the settings shown on the x-axis;
- FIG. 7C 3 ⁇ g of siRNA was electroporated with 3 ⁇ g p.e. of RVG-exosomes at 400V 125 ⁇ F in the volume of buffer shown on the x-axis. All experiments were performed in duplicate.
- FIGS. 8A and 8B Delivery of 2′-OMe oligonucleotide and morpholinos with normal exosomes: Fluorescence imaging of C2C12 cells 24 hours after Cy3-labelled ( FIG. 8A ) 2′-OMe oligonucleotides or ( FIG. 8B ) PMO transfection with or without exosomes.
- FIGS. 9A-9J In vivo delivery of siRNA with targeted exosomes results in CNS-specific gene knockdown: FIGS. 9A-9D : GAPDH qPCR in the striatum, midbrain, cortex, quadriceps muscle, spleen, liver, kidney and heart of mice 3 days after intravenous injection of 150 ⁇ g naked GAPDH siRNA or siRNA encapsulated in unmodified exosomes, MSP-exosomes or RVG-exosomes normalised to untreated controls (100%).
- FIG. 9A-9D GAPDH qPCR in the striatum, midbrain, cortex, quadriceps muscle, spleen, liver, kidney and heart of mice 3 days after intravenous injection of 150 ⁇ g naked GAPDH siRNA or siRNA encapsulated in unmodified exosomes, MSP-exosomes or RVG-exosomes normalised to untreated controls (100%).
- FIG. 9A-9D GAPDH qPCR in the
- FIGS. 9E and 9G GAPDH qPCR of RNA extracted from the striatum, cortex and midbrain of untreated mice (control) or mice injected with empty RVG-exosomes intravenously twice on Day 1 and Day 8 then with RVG-exosome-encapsulated GAPDH siRNA (150 ⁇ g) on Day 22 before sacrificing the mice on Day 25 (3 injections).
- FIGS. 9F and 9G GAPDH qPCR and representative Western blot of mice injected with RVG-exosome encapsulated siRNA (150 ⁇ g) on 2 separate occasions 6 and 3 days before sacrifice.
- the present invention is directed to exosomes, and their use as gene delivery vehicles.
- Exosomes are small membrane-bound vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane.
- the present application is directed to a composition comprising such exosomes.
- the exosomes are between 30 and 100 nm in diameter but can include membrane particles of similar origin up to 200 nm.
- Exosomes as used herein refers to nanoparticles of endosomal origin that are secreted from multivesicular bodies.
- Exosomes are produced by many different types of cells including immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells. Exosomes are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells and tumour cells. Exosomes for use in accordance with the present application can be derived from any suitable cell, including the cells identified above. Exosomes have also been isolated from physiological fluids, such as plasma, urine, amniotic fluid and malignant effusions.
- immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells. Exosomes are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells and tumour cells. Exosomes for use in accordance with the present application can be derived from any suitable cell, including the cells identified above. Exosomes have also been isolated from physiological fluids, such as plasma, urine
- exosomes are derived from DCs, preferably immature DCs.
- Exosomes produced from immature DCs do not express MHC-II, MHC-I or CD86. As such, such exosomes do not stimulate na ⁇ ve T cells to a significant extent and are unable to induce a response in a mixed lymphocyte reaction.
- exosomes produced from immature dendritic cells are ideal candidates for use in delivery of genetic material, particularly for in vivo use, for example, in gene therapy.
- exosomes derived from dendritic cells are provided for use in in vivo delivery of genetic material.
- exosomes can be obtained from any autologous patient-derived, heterologous haplotype-matched or heterologous stem cells so to reduce or avoid the generation of an immune response in a patient to whom the exosomes are delivered.
- Any exosome-producing cell can be utilized for this specific purpose.
- exosomes are produced by many different types of cell and have also been isolated from physiological fluids.
- exosomes can be obtained from any suitable cell type as discussed above, or by isolation from physiological fluids.
- the methods of the present invention comprise isolation of the exosomes from cell culture medium or tissue supernatant.
- Exosomes produced from cells can be collected from the culture medium by any suitable method.
- a preparation of exosomes can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods.
- exosomes can be prepared by differential centrifugation, that is low speed ( ⁇ 20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet exosomes, size filtration with appropriate filters (for example, 0.22 ⁇ m filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
- the exosomes are loaded with exogenous genetic material.
- exosomes are prepared and then loaded with the desired genetic material for delivery.
- Suitable genetic material for delivery includes exogenous DNA plasmid and siRNA. Suitable genetic material also includes modified oligonucleotides and other RNA interference effector moieties such as miRNA and shRNA.
- the genetic material loaded into the exosome is not genetic material that is typically associated with the exosomes, for example, the nucleic acid is preferably not an mRNA or a miRNA which is incorporated into an exosome on its production from a cell.
- the present invention is concerned with the ability to load genetic material into an exosome preparation that has already been isolated from cells.
- exogenous genetic material refers to genetic material inclusive of nucleic acids that is not normally associated with exosomes.
- the nucleic acid material is plasmid DNA or other nucleic acids such as siRNA and modified oligonucleotides which are not typically found in exosomes.
- Nucleic acids for incorporation into the exosomes may be single or double stranded.
- Single-stranded nucleic acids include those with phosphodiester, 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, and/or phosphorothioate backbone chemistry.
- double-stranded nucleic acids are introduced including for example plasmid DNA and small interfering RNAs (siRNAs).
- the genetic material to be loaded into the exosomes is chosen on the basis of the desired effect of that genetic material on the cell into which it is intended to be delivered and the mechanism by which that effect is to be carried out.
- the nucleic acid may be useful in gene therapy, for example in order to express a desired gene in a cell or group of cells.
- Such nucleic acid is typically in the form of plasmid DNA or viral vector encoding the desired gene and operatively linked to appropriate regulatory sequences such as promoters, enhancers and the like such that the plasmid DNA is expressed once it has been delivered to the cells to be treated.
- diseases susceptible to gene therapy include haemophilia B (Factor IX), cystic fibrosis (CTFR) and spinal muscular atrophy (SMN-1).
- Nucleic acid can also be used for example in immunisation to express one or more antigens against which it is desired to produce an immune response.
- the nucleic acid to be loaded into the exosome can encode one or more antigens against which is desired to produce an immune response, including but not limited to tumour antigens, antigens from pathogens such as viral, bacterial or fungal pathogens.
- Nucleic acid can also be used in gene silencing. Such gene silencing may be useful in therapy to switch off aberrant gene expression or in animal model studies to create single or more genetic knock outs.
- nucleic acid is provided in the form of siRNAs.
- RNAi molecules including siRNAs can be used to knock down DMPK with multiple CUG repeats in muscle cells for treatment of myotonic dystrophy.
- plasmids expressing shRNA that reduces the mutant Huntington gene (htt) responsible for Huntington's disease can be delivered with neuron specific exosomes.
- Other target genes include BACE-1 for the treatment of Alzheimer's disease.
- Some cancer genes may also be targeted with siRNA or shRNAs, such as ras, c-myc and VEGFR-2.
- Brain targeted siRNA loaded exosomes may be particularly useful in the silencing of BACE-1 in Alzheimer's disease, silencing of alpha-synuclein in Parkinson's disease, silencing of htt in Huntingdon's disease and silencing of neuronal caspase-3 used in the treatment of stroke to reduce ischaemic damage.
- Antisense modified oligonucleotides including 2′-O-Me compounds and PNA can be used.
- such oligonucleotides can be designed to induce exon-skipping for example the mutant dystrophin gene can be delivered to muscle cells for the treatment of Duchenne Muscular Dystrophy, antisense oligonucleotides which inhibit hairpin loops, for example in the treatment of myotonic dystrophy and trans-splicing oligonucleotides, for example for the treatment of spinal muscular atrophy.
- the exogenous genetic material can be introduced into the exosomes by a number of different techniques.
- the exosomes are loaded by electroporation or the use of a transfection reagent.
- the present inventors have identified that despite the small size of exosomes, it is still possible to use electroporation to load the exosomes with the exogenous genetic material. This is surprising in view of the small size of the exosomes compared to cells. Extrapolation of the voltages used for electroporation of cells to take into account the size of the exosomes would suggest that excessively high voltages would be required for electroporation of exosomes.
- Typical voltages are in the range of 20V/cm to 1000V/cm, such as 20V/cm to 100V/cm with capacitance typically between 25 ⁇ F and 250 ⁇ F, such as between 25 ⁇ F and 125 ⁇ F.
- the inventors have also identified that it is possible to load exosomes using transfection agents. Despite the small size of the exosomes, conventional transfection agents can be used for transfection of exosomes with genetic material.
- Preferred transfection reagents for use in accordance with the present invention include cationic liposomes.
- the present invention also relates to the targeting of exosomes to a desired cell type or tissue.
- This targeting is achieved by expressing on the surface of the exosome a targeting moiety which binds to a cell surface moiety expressed on the surface of the cell to be targeted.
- the targeting moiety is a peptide which is expressed as a fusion protein with a transmembrane protein typically expressed on the surface of the exosome.
- the exosomes can be targeted to particular cell types or tissues by expressing on their surface a targeting moiety such as a peptide.
- Suitable peptides are those which bind to cell surface moieties such as receptors or their ligands found on the cell surface of the cell to be targeted.
- suitable targeting moieties are short peptides, scFv and complete proteins, so long as the targeting moiety can be expressed on the surface of the exosome and does not interfere with insertion of the membrane protein into the exosome.
- the targeting peptide is heterologous to the transmembrane exosomal protein.
- Peptide targeting moieties may typically be less than 100 amino acids in length, for example less than 50 amino acids in length, less than 30 amino acids in length, to a minimum length of 10, 5 or 3 amino acids.
- Targeting moieties can be selected to target particular tissue types such as muscle, brain, liver, pancreas and lung for example, or to target a diseased tissue such as a tumour.
- the exosomes are targeted to brain tissue.
- targeting moieties include muscle specific peptide, discovered by phage display, [33] to target skeletal muscle, a 29 amino acid fragment of Rabies virus glycoprotein that binds to the acetylcholine receptor [36] or a fragment of neural growth factor that targets its receptor [37] to target neurons and secretin peptide that binds to the secretin receptor can be used to target biliary and pancreatic epithelia [38].
- immunoglobulins and their derivatives, including scFv antibody fragments can also be expressed as a fusion protein to target specific antigens, such as VEGFR for cancer gene therapy.
- natural ligands for receptors can be expressed as fusion proteins to confer specificity, such as NGF which binds NGFR and confers neuron-specific targeting.
- the peptide targeting moiety is expressed on the surface of the exosome by expressing it as a fusion protein with an exosomal transmembrane protein.
- a number of proteins are known to be associated with exosomes; that is they are incorporated into the exosome as it is formed.
- the preferred proteins for use in accordance with the present invention are those which are transmembrane proteins.
- Examples include but are not limited to Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3, CD2, CD36, CD40, CD40L, CD41a, CD44, CD45, ICAM-1, Integrin alpha4, L1CAM, LFA-1, Mac-1 alpha and beta, Vti-1A and B, CD3 epsilon and zeta, CD9, CD18, CD37, CD53, CD63, CD81, CD82, CXCR4, FcR, GluR2/3, HLA-DM (MHC II), immunoglobulins, MHC-I or MHC-II components, TCR beta and tetraspanins.
- MHC II HLA-DM
- the transmembrane protein is selected from Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3.
- the transmembrane protein is Lamp-2.
- the sequence of Lamp-2 is set out in SEQ ID No 1.
- polypeptides of the invention relate to general features of all polypeptides of the invention, and in particular to variations, alterations, modifications or derivatisations of amino acid sequence which are included within the polypeptides of the invention. It will be understood that such variations, alterations, modifications or derivatisations of polypeptides as are described herein are subject to the requirement that the polypeptides retain any further required activity or characteristic as may be specified subsequent sections of this disclosure.
- Variants of polypeptides of the invention may be defined by particular levels of amino acid identity which are described in more detail in subsequent sections of this disclosure.
- Amino acid identity may be calculated using any suitable algorithm.
- PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
- This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence.
- T is referred to as the neighbourhood word score threshold (Altschul et al, supra).
- These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them.
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci . USA 90: 5873-5787.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, 387-395).
- variants of polypeptides of the invention also includes substitution variants.
- substitution variants preferably involve the replacement of one or more amino acids with the same number of amino acids and making conservative amino acid substitutions.
- an amino acid may be substituted with an alternative amino acid having similar properties, for example, another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid or another aliphatic amino acid.
- polypeptides for use in the invention may be modified to include non-naturally occurring chemistries or to increase the stability and targeting specificity of the compound.
- polypeptides When the polypeptides are produced by synthetic means, such amino acids may be introduced during production.
- the polypeptides may also be modified following either synthetic or recombinant production.
- Variant polypeptides as described in this section are those for which the amino acid sequence varies from that in SEQ ID NO: 1, but which retain the ability to be inserted into the membrane of an exosome.
- the variant sequences typically differ by at least 1, 2, 3, 5, 10, 20, 30, 50, 100 or more mutations (which may be substitutions, deletions or insertions of amino acids). For example, from 1 to 100, 2 to 50, 3 to 30 or 5 to 20 amino acid substitutions, deletions or insertions may be made, provided the modified polypeptide is inserted into the membrane of an exosome.
- polypeptides which are variants of Lamp-2 have more than about 50%, 55% or 65% identity, preferably at least 70%, at least 80%, at least 90% and particularly preferably at least 95%, at least 97% or at least 99% identity, with the amino acid sequence of SEQ ID NO: 1.
- the identity of variants of SEQ ID NO: 1 may be measured over a region of at least 30, 50, 100, 200, 250, 300, 350 or more contiguous amino acids of the sequence shown in SEQ ID NO: 1, or more preferably over the full length of SEQ ID NO: 1, excluding the signal sequence.
- the fragment of the Lamp-2 polypeptide used in the invention is typically at least 55 amino acids, 100, 150, 200, or 250 amino acids in length.
- the exosomal transmembrane protein is modified to incorporate a targeting moiety.
- the exosomal transmembrane protein is expressed as a fusion protein comprising the targeting moiety.
- the targeting moiety is incorporated into the transmembrane protein such that it is positioned in the portion of the transmembrane protein present on the surface of the exosomes.
- the exosomal transmembrane protein is Lamp-2 and the targeting moiety is expressed as a fusion protein, wherein the targeting moiety is present near the N-terminus of Lamp-2 protein for example within 30, or within 20 amino acids of the Lamp-2 N terminal amino acid, not including the signal sequence.
- Spacer or linker sequences may be provided between the targeting moiety and the remainder of the transmembrane protein for example to avoid interference from the targeting moiety in the folding of the transmembrane protein.
- Linker or spacer sequences are typically 1 to 10 amino acids in length, typically 1 to 8 amino acids in length such as 2, 3 or 4 amino acids in length.
- Suitable amino acids for incorporation in linkers are alanine, arginine, serine or glycine.
- Suitable linkers include Ala-Arg and Ser-Gly-Gly.
- the transmembrane protein is Lamp-2 and the targeting moiety is present at or near the N-terminus of the protein, separated from Lamp-2 with linker sequences.
- the targeting moiety is introduced into the exosome by expressing the fusion protein comprising the targeting moiety and exosomal transmembrane protein within a cell used to produce the exosomes. Expression of this fusion protein in the cell, allows for the fusion protein to be incorporated into the exosome as it is produced from the cell.
- a polynucleotide construct such as a DNA plasmid, which expressed the fusion protein is transfected into the cell.
- Any suitable method can be used for introduction of the polynucleotide construct into the cell.
- the polynucleotide construct includes suitable promoter sequences so that the encoded fusion protein is expressed in the cell.
- Signal peptide sequences are also included so that the protein is incorporated into the membrane of the endoplasmic reticulum as it is produced. The membrane protein is then subsequently exported to the exosomal/lysomal compartment before incorporation into the exosome.
- the signal sequence is typically a signal peptide sequence for an exosomal transmembrane protein.
- the signal peptide sequence is preferably derived from Lamp-2, for example as shown in the Examples.
- Preferred cells for production of exosomes are discussed in more detail above.
- a preferred cell such as an immature dendritic cells is transfected with a polynucleotide construct as described above, such that the fusion protein of the invention is expressed in the cell.
- Exosomes produced by the cell can then be collected.
- Such exosomes have the fusion protein inserted into the membrane such that the exosomes are targeted to the desired tissue or cell type through the targeting moiety.
- Exosomes produced from cells can be collected from the culture medium by any suitable method.
- a preparation of exosomes can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods.
- exosomes can be prepared by differential centrifugation, that is low speed ( ⁇ 20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet exosomes, size filtration with appropriate filters (for example, 0.22 ⁇ m filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
- the targeted exosomes are loaded with exogenous genetic material.
- exosomes are prepared with a targeting moiety as described herein and then loaded with the desired genetic material for delivery or described above.
- a specific targeting moiety does not need to be included in the exosome.
- exosomes may be administered directly to the site where therapy is required.
- exosomes may contain genetic material encoding immunogens
- direct targeting to a specific site may not be required and delivery, for example, intradermal or muscular delivery may be sufficient to generate the desired immune response without targeting exosomes to any specific cell type.
- no targeting moiety is included on the surface of the exosomes.
- the exosomes are selected such that they are more likely to target a specific tissue type.
- exosomes derived from different cells may have natural affinities for specific cell subtypes as required by their physiological function such as the well-established affinity of mature dendritic cell-derived exosomes to T-cells. This affinity may be utilized to specifically deliver above-mentioned cargo to a tissue.
- constructs of the invention may be administered by any suitable means.
- Administration to a human or animal subject may be selected from parenteral, intramuscular, intracerebral, intravascular, subcutaneous, or transdermal administration.
- the method of delivery is by injection.
- the injection is intramuscular or intravascular (e.g. intravenous).
- a physician will be able to determine the required route of administration for each particular patient.
- the constructs are preferably delivered as a composition.
- the composition may be formulated for parenteral, intramuscular, intracerebral, intravascular (including intravenous), subcutaneous, or transdermal administration.
- Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
- the constructs of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharmaceutically acceptable carriers or excipients and the like in addition to the exosomes.
- a “pharmaceutically acceptable carrier” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject.
- Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc); fillers (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g.
- compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions.
- the compositions may contain additional compatible pharmaceutically-active materials or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- additional materials useful in physically formulating various dosage forms of the composition of present invention such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- such materials when added, should not unduly interfere with the biological activities of the components of the compositions provided herein.
- a therapeutically effective amount of composition is administered.
- the dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen.
- a physician will be able to determine the required route of administration and dosage for any particular patient.
- Optimum dosages may vary depending on the relative potency of individual constructs, and can generally be estimated based on EC50s found to be effective in vitro and in in vivo animal models. In general, dosage is from 0.01 mg/kg to 100 mg per kg of body weight.
- a typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to 10 mg/kg of body weight, according to the potency of the specific construct, the age, weight and condition of the subject to be treated, the severity of the disease and the frequency and route of administration.
- Different dosages of the construct may be administered depending on whether administration is by intramuscular injection or systemic (intravenous or subcutaneous) injection.
- the dose of a single intramuscular injection is in the range of about 5 to 20 ⁇ g.
- the dose of single or multiple systemic injections is in the range of 10 to 100 mg/kg of body weight.
- the patient may have to be treated repeatedly, for example once or more daily, weekly, monthly or yearly. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the construct in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy, wherein the construct is administered in maintenance doses, ranging from 0.01 mg/kg to 100 mg per kg of body weight, once or more daily, to once every 20 years.
- Exosomes are harvested daily over the next 2 days by centrifugation of culture supernatant, first at 10,000 g to remove cellular debris, then at 120,000 g to pellet exosomes. The exosomes are then resuspended in an appropriate amount of 0.1M ammonium acetate buffer.
- the exosomes produced were consistent and physically homogenous, with a size distribution peaking at 80 nm in diameter as determined by electron microscopy ( FIG. 1A ), Western with an antibody against an exosomal protein (Lamp2b) ( FIG. 1B ) and dynamic light scattering ( FIG. 1C ).
- FIG. 2A illustrates how a targeting ligand is inserted into Lamp2b.
- the targeting ligand needs to be attached to the N-terminus after the signal peptide.
- the signal peptide is required for membrane insertion but is cleaved off in the mature protein.
- the targeting peptide is flanked by linkers (Ala-Arg- ⁇ Targeting Peptide ⁇ -Ser-Gly-Gly) to prevent the targeting peptide from influencing the folding of the Lamp2b protein.
- the targeting peptide should be located on the external surface of the exosomes, hence conferring targeting capabilities to the exosomes.
- Three different peptides the neuron-specific rabies viral glycoprotein (RVG) peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG (SEQ ID No: 6)) [32], a muscle-specific peptide (MSP) identified by in vivo phage display (ASSLNIA) (SEQ ID No: 9) [33], and a FLAG epitope—were separately cloned into Lamp2b and transfected into the dendritic cells 4 days before exosome purification.
- RVG neuron-specific rabies viral glycoprotein
- MSP muscle-specific peptide identified by in vivo phage display
- FLAG epitope were separately cloned into Lamp2b and transfected into the dendritic cells 4 days before exosome purification.
- Both MSP and RVG were selected for organ specificity while the FLAG epitope in the targeting ligand site was used to differentiated modified Lamp2b and unmodified exogenous Lamp2b.
- a major hindrance to the ability to express targeting ligands on the surface of exosomes is that primary dendritic cells are difficult to transfect and can potentially differentiate after transfection. Infection with viral vectors is not ideal either as dendritic cells are likely to be activated by the virus [30], hence producing immunostimulatory molecules that will be incorporated into the resultant exosomes.
- Mints Bio's TransIT-LT1 reagent was selected as it appeared to efficiently transduce dendritic cells, with a 49900 fold increase in eGFP mRNA normalized to murine GAPDH over the addition by pEGFP-NAD, an eGFP-expressing plasmid, alone without transfection reagents. More importantly, this transfection does not appear to significantly activate dendritic cells based on observation of cell morphology. Immature dendritic cells are compact rounded cells with low surface area-to-volume ratios while activated dendritic cells have characteristic dendritic extensions and large surface area-to-volume ratios [31].
- Transfection of dendritic cells was performed with 5 ⁇ g of pEGFP-NAD or pLamp2b derivatives and 5 ⁇ l of TransIT LT1 transfection reagent (Minis Bio) in a 6-well plate with 10 6 cells on Day 4 after harvesting. Medium is changed on Day 7 and exosomes are isolated from culture supernatant on Day 8.
- an EGFP-expressing plasmid pEGFP-NAD
- pEGFP-NAD plasmid
- Cy5-labeled anti-GAPDH siRNA and unlabelled anti-mouse cyclophilin B were used as RNA cargo
- a Cy3-labeled 2′-OMe oligonucleotide and a Cy3-labelled morpholino designed for exon skipping in mdx mice gift from Haifang Yin
- Circular and linearized pEGFP-NAD were electroporated with exosomes and then exposed to DNase I for 10 minutes. If the DNA was successfully loaded in to the exosomes, the DNase will be unable to digest the DNA as it is unable to access the interior of the exosomes; conversely, if the DNA was not located within the exosomes, the presence of DNase will result in DNA degradation and the loss of a plasmid signal.
- electroporation with exosomes appear to protect circular DNA plasmid from degradation but not linear DNA ( FIG. 3A ) and that lower capacitance appears to increase uptake of DNA into exosomes ( FIG. 3B ).
- the DNase was inactivated by 10 ⁇ l of STOP buffer (Promega) before the DNase protection assay or the direct addition of the entire solution to Neuro2A or C2C12 cells in a 24-well format.
- Three different transfection reagents (1:Lipofectamine 2000 (Invitrogen); 2:TransIT LT1 (Minis Bio) 3: TurboFect (Fermantas)) were used to deliver open circular pEGFP-NAD into exosomes and preliminary results suggest that Reagent 3 resulted in significant DNase protection ( FIG. 3D ), suggesting that transfection reagents can be used to load genetic cargo into exosomes.
- transfection reagent may serve to condense the plasmids as well as provide additional hydrophobic molecules to increase the size of the exosomes.
- DNase protection Assay 20 ⁇ l of the electroporated solution was added to 70 ⁇ l of distilled water, 10 ⁇ l of RQ DNase Buffer and 1 ⁇ l RQ DNase I (Promega) and incubated at 37° C. for 10 min before inhibiting the reaction with 10 ⁇ l of STOP buffer. 10 ⁇ l of each sample was run on each lane in a 0.8% agarose TAE gel.
- transfection reagent 3 FIG. 3C
- pEGFP-NAD without exosomes, with wild type exosomes, or with exosomes harvested from dendritic cells transfected with pLamp2b-RVG (RVG-exosomes) or pLamp2b-MSP (MSP-exosomes) and DNase treated the mixture after incubation, including the sample with pEGFP-NAD and transfection reagent alone.
- siRNAs should also be readily taken up by exosomes.
- exosomes would also be able to deliver siRNAs.
- a well characterized Cy5-labeled siRNA against GAPDH was electroporated into wild type, RVG- and MSP-exosomes and applied directly to Neuro2A and C2C12 cells. The cells were then imaged after 2 days and showed higher fluorescence when compared to control cells treated with siRNA and unelectroporated exosomes alone ( FIGS. 5A and 5B ).
- FIGS. 5C and 5D Similar protocols were followed for the transfection of cells with exosomes and qRT-PCR of GAPDH normalised to 18S RNA ( FIGS. 5C and 5D ) demonstrated significant knockdown in targeted exosomes compared to controls after 2 days, suggesting that the siRNAs were released into the cytoplasm after transfection to actively repress the endogenous target and that the targeting moiety effectively delivered the siRNA to the desired cell type i.e. neuron-specific RVG to neuronal Neuro2A cells and muscle specific MSP to C2C12 myoblasts. This knockdown was further confirmed with Western blot of the GAPDH protein ( FIGS. 5E and 5F ).
- the resultant pellet was resuspended in 100 ⁇ l of double distilled water, which is predicted to lyse the exosomes via osmotic pressure and release the encapsulated siRNA within.
- the siRNA content was then measured with a fluorescence plate reader with 560 nm excitation and 610 nm emission and the retained siRNA quantified against a standard curve of pure siRNA in water. As shown in FIG. 7 , over 20% of initial siRNA (0.73 ⁇ g) was retained after electroporation at 400V and 125 ⁇ F, the optimum electroporation setting. Furthermore, concentrating the mixture by decreasing the amount of electroporation buffer appeared to increase the loading up to a certain level.
- Dendritic cells were cultured in DC medium (DMEM Glutamax, 10% FBS, non-essential amino acids # and antibiotics).
- C2C12 cells were cultured in DMEM Glutamax supplemented with 20% FBS and antibiotics.
- Neuro2A cells were cultured in EMEM supplemented with 10% FBS. All cells were incubated at 37° C. in 5% CO 2 .
- Lamp2b was cloned with cDNA from C2C12 cells and XhoI and BspEI restriction sites were inserted after the signal peptide sequence together with glycine linkers. The full construct was then cloned downstream of the CMV promoter with NheI and HindIII restriction sites into a pEGFP-C1 vector, removing the eGFP in the process. Primers designed to encode RVG [32], MSP [33] and FLAG tag were used to introduce the targeting ligands between XhoI and BspEI at the N-terminus of Lamp2b ( FIG. 6A ). Primer sequences for the peptides were
- RVG (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (SEQ ID No: 6): Forward (SEQ ID No: 7) 5′- tcgatacaccatttggatgcccgagaatccgagaccagggacaccttgtgacatttttaccaatagcagagg gaagagagcatccaacgggt -3′ Reverse (SEQ ID No: 8) 5′- ccggacccgttggatgctctcttccctctgctattggtaaaatgtcacaaggtgtccctggtctcggattctc gggcatccaaatggtgta -3′ MSP(ASSLNIA) (SEQ ID No: 9): Forward (SEQ ID No: 10) 5′- tcgagccagcagcctgaacatcgcct -3′ Reverse (SEQ ID No: 11)
- Transfection of dendritic cells was performed with 5 ⁇ g of pEGFP-NAD or pLamp2b derivatives and 5 ⁇ l of TransIT LT1 transfection reagent (Minis Bio) in a 6-well plate with 10 6 cells on Day 4 after harvesting and isolation of exosomes is done on Day 8.
- Reverse transcription was performed with 500 ng of RNA and random primer using Precision Reverse Transcription Kit (Primer Design) as per manufacturer's instruction.
- qPCR experiments were performed on an ABI7000 thermal cycler in 20 ⁇ l reactions, with 0.5 nM of each primer and 2 ⁇ l of each cDNA preparation, using Precision qPCR Mastermix (Primer Design) as per manufacturer's instructions.
- 1 ⁇ g of the pEGFP-NAD plasmid was mixed with 1 ⁇ l of the transfection reagent, 3 of exosomes and topped up to 100 ⁇ l with DMEM.
- the solution was incubated for 3 hours at 37° C. and then subjected to DNase treatment for 10 minutes at 37° C. with the addition of 1 ⁇ l of RQ DNase I (Promega) and 10 ⁇ l of RQ DNase buffer.
- the DNase was inactivated by 10 ⁇ l of STOP buffer (Promega) before the direct addition of the entire solution to Neuro2A cells in a 24-well format.
- Exosomes were loaded to a protein concentration of 6 ⁇ g in 200 ⁇ l of electroporation buffer (1.15 mM potassium phosphate pH 7.2, 25 mM KCl, 21% Optiprep) and 2 ⁇ g of pEGFP-NAD or 100 pmol of cyclophilin siRNA was added, mixed and electroporated in a 4 mm cuvette.
- electroporation buffer 1.15 mM potassium phosphate pH 7.2, 25 mM KCl, 21% Optiprep
- pEGFP-NAD or 100 pmol of cyclophilin siRNA was added, mixed and electroporated in a 4 mm cuvette.
- 20 ⁇ l of the electroporated solution was added to 70 ⁇ l of distilled water, 10 ⁇ l of RQ DNase Buffer and 1 ⁇ l RQ DNase I (Promega) and incubated at 37° C. for 10 min before inhibiting the reaction with 10 ⁇ l of STOP buffer. 10 ⁇
- Immunologically inert exosomes were harvested from murine bone marrow-derived dendritic cells and targeting moieties—muscle-specific peptide (MSP) and neuron-specific rabies viral glycoprotein (RVG), were genetically engineered onto Lamp2b, an exosomal membrane protein, to alter tissue specificity of these exosomes, as described above.
- MSP muscle-specific peptide
- RVG neuron-specific rabies viral glycoprotein
- BACE-1 a key enzyme in the pathogenesis of Alzheimer's disease (AD) was targeted to evaluate the therapeutic potential of this technology.
- AD Alzheimer's disease
- 150 ⁇ g of RVG-exosomes and 150 ⁇ g of each BACE-1 siRNA were electroporated, purified and resuspended in 5% glucose before delivery.
- Significant mRNA (72% ⁇ 18%) and protein (60% ⁇ 13%) knockdown in cortex 3 days after administration FIGS. 9H and 9I ).
Abstract
Description
- This application is a division of U.S. application Ser. No. 16/857,803, filed on Apr. 24, 2020, which is a continuation of U.S. application Ser. No. 16/264,257, filed on Jan. 31, 2019, now U.S. Pat. No. 10,704,047 issued on Jul. 7, 2020, which is a continuation of U.S. application Ser. No. 14/847,853, filed on Sep. 8, 2015, now U.S. Pat. No. 10,233,445 issued on Mar. 19, 2019 which is a continuation of U.S. application Ser. No. 13/264,485, filed Oct. 14, 2011, now abandoned, which is the U.S. National Stage of International Application No. PCT/GB2010/000762, filed Apr. 15, 2010, which designates the U.S., published in English, and claims priority under 35 U.S.C. §§ 119 or 365(c) to GB Application No. 0906693.7, filed Apr. 17, 2009 and GB Application No. 0906692.9, filed Apr. 17, 2009. The entire teachings of the above applications are incorporated herein by reference.
- This application incorporates by reference the Sequence Listing contained in the following ASCII text file being submitted concurrently herewith:
-
- a) File name: 47761000004_SequenceListing_Corrected; created May 22, 2020, 16 KB in size.
- The present invention relates to compositions for the delivery of nucleic acid or genetic material. In particular the present invention relates to exosomes, loaded with genetic material and methods of producing them.
- Nucleic acids are routinely used in gene therapy for the replacement of non-functional genes [1] and for neutralization of disease-causing mutations via RNA interference (RNAi) effector molecules such as miRNAs [2], shRNAs [3] and siRNAs [4]. As naked DNA and RNA are difficult to deliver in vivo due to rapid clearance [5], nucleases [6], lack of organ-specific distribution and low efficacy of cellular uptake, specialized gene delivery vehicles are usually used for delivery.
- Viral vectors and cationic liposomes are at the forefront of delivery vehicle technology and have been relatively successful with a large number of these delivery vehicles already in clinical trial [7]. Despite these successes, there remain significant limitations that restrict many applications, the most significant of which are immune recognition [8, 9, 10] for most viral vectors and mutagenic integration [11] for viruses such as lentiviruses; and inflammatory toxicity and rapid clearance for liposomes [12, 13, 14, 15]. Recognition by the innate immune system leads to acute inflammatory responses, which may require the use of immunosuppression strategies to overcome uptake and re-administration issues of current strategies [16, 17, 18] potentially exposing patients to unwarranted risks of opportunistic infections. Antibodies generated against the delivery vehicles also dramatically decrease transgene expression on subsequent administration [19].
- The inherent risks and limitations of current strategies have generally limited them to life-threatening diseases of which the benefits of therapy clearly outweigh the risks, such as severe combined immunodeficiency [20], to diseases in special environments, such as immuno-privileged sites like the eye [1], or for genetic vaccination [21]. However, for genetic diseases which are chronic and debilitating but not life-threatening, such as myotonic dystrophy, a much lower risk profile and the ability to sustain corrective gene therapy for decades, not years, is required for curative intervention. An example of a potentially unacceptable risk for this class of diseases is immunosuppression strategies discussed above, highlighted by the death of a healthy patient in a recent AAV gene therapy trial for rheumatoid arthritis due to an opportunistic infection caused by immunosuppressants [22] taken by the subject unbeknownst to the trial administrators. With the increasing number of diseases shown to possess a genetic component, including obesity, heart disease and psychiatric illnesses, there is tremendous potential for the modification of susceptibility genes for preemptive genetic solutions, but only if the risks are further reduced and long-term sustainability is achieved. Hence, it is imperative to develop technologies that are able to avoid immune recognition and inflammation, while retaining good delivery efficiencies, in order to expand the use of gene therapy beyond lethal diseases.
- One of the solutions may lie in the use of exosomes for gene delivery. Exosomes are small membrane-bound vesicles (30-100 nm) of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Exosome production has been described for many immune cells including B cells, T cells, and dendritic cells (DCs). Exosomes derived from B lymphocytes and mature DCs express MHC-II, MHC-I, CD86 and ICAM-1 [23, 24], and have been used to induce specific anti-tumor T cytotoxic responses and anti-tumor immunity in experimental models and clinical trials [24, 25]. The potential of exosome-mediated gene delivery has been shown with delivery of murine mRNAs and miRNAs to human mast cells [26] and glioma-derived exosomes [27] have been demonstrated to transfer mRNAs produced by exogenous DNA plasmids to heterologous cells, but loading and delivery of exogenous DNA, siRNAs and other modified oligonucleotides has not been demonstrated as yet.
- The present inventors have successfully loaded exosomes with exogenous genetic material, and in particular exogenous plasmid DNA, siRNA and modified oligonucleotides. Thus, the present invention relates to methods for loading exosomes with exogenous genetic material, the exosomes loaded with such exogenous genetic material, and their use in delivery of the nucleic acid for gene therapy and gene silencing.
- The present inventors have also successfully introduced targeting moieties into exosomes so that the exosomes can be targeted to a selected tissue. Thus, the present invention relates to exosomes which have a targeting moiety expressed on their surface and to fusion proteins comprising exosomal transmembrane proteins and a targeting moiety, and to nucleic acid constructs encoding such fusion proteins. The exosomes can be loaded with exogenous genetic material, and used in delivery of the nucleic acid for gene therapy and gene silencing.
- In accordance with one aspect of the present invention, there is provided a composition comprising an exosome, wherein the exosome is loaded with exogenous genetic material.
- In another aspect, the invention provides a composition comprising an exosome containing genetic material, wherein the exosome is derived from an immature dendritic cell, for use in a method of delivering the genetic material in vivo.
- In another embodiment, the invention provides a method of loading exosomes with genetic material comprising providing a composition of exosomes, and loading the exosomes with genetic material by electroporation.
- In another embodiment, the invention provides a method of loading exosomes with genetic material comprising providing a composition of exosomes and loading the exosomes with nucleic acid by transfection, using a cationic liposome transfection agent.
- In accordance with another aspect of the present invention, there is provided a composition comprising an exosome, wherein said exosome comprises a targeting moiety expressed on the surface of the exosome.
- In another aspect, the invention provides a polypeptide comprising an exosomal transmembrane protein, and a heterologous targeting peptide, wherein the targeting peptide binds to a moiety present on the surface of the cell to be targeted, and wherein when the polypeptide is present in an exosome, the targeting peptide is present on the surface of the exosome.
- In another embodiment, the invention provides a polynucleotide construct encoding a polypeptide, wherein the construct comprises polynucleotide encoding a 5′ exosomal transmembrane signal sequence, for example an endoplasmic reticulum-targeting signal peptide operatively linked to polynucleotide encoding the polypeptide of the invention.
- In another embodiment, the invention provides a method of targeting an exosome to a selected tissue or cell type comprising transfecting a host cell with a polynucleotide construct according to the invention, expressing the construct in the host cell, and obtaining exosomes from the host cell in which the construct has been expressed.
-
FIGS. 1A-1C . Characterization of exosomes from immature dendritic cells:FIG. 1A : Electron micrographs of exosomes stained with 2% uranyl acetate (exosomes negatively stained);FIG. 1B : Western blot of exosomes probed with anti-Lamp2, a membrane protein present in exosomes;FIG. 1C : Dynamic light scattering size measurements of purified dendritic cell exosomes in PBS from 5 different purifications -
FIGS. 2A-2E . Transfection of dendritic cells:FIG. 2A : Modification of Lamp-2b for transfection into dendritic cells. (SP=Signal Peptide; TP=targeting peptide; TM=transmembrane; CT=cytoplasmic tail);FIG. 2B : Western blot with anti-FLAG or anti-Lamp2 in untransfected dendritic cells (CTRL) or cell transfected with pLamp2b-FLAG (FLAG-Lamp2b) and the exosomes harvested from these cells;FIG. 2C : qRT-PCR of dendritic cells transfected with pLamp2b-MSP, -RVG or nothing using primers specific for MSP and RVG sequences;FIG. 2D : Western blot with anti-Lamp1 after incubation of normal exosomes and FLAG exosomes with anti-FLAG beads or anti-AGO1 beads (non-binding control) in an exosome pulldown assay;FIG. 2E : Dynamic light scattering size measurements of purified MSP-exosomes. -
FIGS. 3A-3D . Electroporation of plasmid with exosome followed by DNase protection assay:FIG. 3A : DNase protection assay on various treatments of exosomes and the pEGFP-NAD plasmid. Linear DNA was made by cutting pEGFP-NAD with EcoRI. (Pre=exosomes pre-electroporated before addition of plasmid);FIG. 3B : Comparison of DNase degradation by DNase with circular plasmid at different electroporation settings;FIG. 3C : DNase protection assay after transfection of pEGFP-NAD with different transfection reagents;FIG. 3D : DNase protection assay after transfection of exosomes with transfection reagents 1-3 and pEGFP-NAD (see materials and methods). -
FIGS. 4A-4C . Exosome-mediated delivery of pEGFP-NAD into cells:FIG. 4A : Transfection of Neuro2A cells with wild-type exosomes and exosomes expressing RVG-Lamp2b (RVG-exosomes) transfected with pEGFP-NAD compared to plasmid alone after DNase treatment.FIGS. 4B and 4C : qRT-PCR quantification of fold change of eGFP after transfection with normal, RVG- or MSP-exosomes over transfection reagent alone. -
FIGS. 5A-5D . Knockdown of GAPDH with exosome-mediated siRNA delivery:FIGS. 5A and 5B : Representative images of Cy5-labelled GAPDH siRNA applied on to Neuro2A (FIG. 5A ) and C2C12 (FIG. 5B ) cells with normal or modified exosomes. Unelectroporated exosomes and siRNA were added as controls.FIGS. 5C and 5D : qPCR of GAPDH levels in Neuro2A cells and C2C12 cells harvested 2 days after transfection with siRNA alone (siRNA), siRNA with lipofectamine 2000 (Invitrogen) (siRNA+LP), normal exosomes (Exosomes), MSP exosomes (MSP exos) and RVG exosomes (RVG exos). (*p<0.05) Representative Western blots of GAPDH levels after similar transfections were performed (data not shown). -
FIGS. 6A-6B . Knockdown of cyclophilin B with exosome-mediated siRNA delivery:FIGS. 6A and 6B : qPCR of cyclophilin B levels in Neuro2A cells and C2C12 cells harvested 2 days after transfection with siRNA alone (siRNA), siRNA with lipofectamine 2000 (Invitrogen) (siRNA+LP), normal exosomes (Exosomes), MSP exosomes (MSP exos) and RVG exosomes (RVG exos). (*p<0.05) Representative Western blots of cyclophilin B levels after similar transfections were performed (data not shown). -
FIGS. 7A-7C . Retention of Cy3 and Cy5 labeled siRNA after electroporation with exosomes:FIG. 7A : Fluorescence correlates linearly to siRNA mass.FIGS. 7B and 7C : Absolute mass of labeled siRNA retained afterFIG. 7B , 3 μg of siRNA was electroporated with 3 μg p.e. of RVG-exosomes in 200 μl of buffer at the settings shown on the x-axis;FIG. 7C : 3 μg of siRNA was electroporated with 3 μg p.e. of RVG-exosomes at400V 125 μF in the volume of buffer shown on the x-axis. All experiments were performed in duplicate. -
FIGS. 8A and 8B . Delivery of 2′-OMe oligonucleotide and morpholinos with normal exosomes: Fluorescence imaging of C2C12 cells 24 hours after Cy3-labelled (FIG. 8A ) 2′-OMe oligonucleotides or (FIG. 8B ) PMO transfection with or without exosomes. -
FIGS. 9A-9J . In vivo delivery of siRNA with targeted exosomes results in CNS-specific gene knockdown:FIGS. 9A-9D : GAPDH qPCR in the striatum, midbrain, cortex, quadriceps muscle, spleen, liver, kidney and heart ofmice 3 days after intravenous injection of 150 μg naked GAPDH siRNA or siRNA encapsulated in unmodified exosomes, MSP-exosomes or RVG-exosomes normalised to untreated controls (100%).FIG. 9E : GAPDH qPCR of RNA extracted from the striatum, cortex and midbrain of untreated mice (control) or mice injected with empty RVG-exosomes intravenously twice onDay 1 and Day 8 then with RVG-exosome-encapsulated GAPDH siRNA (150 μg) onDay 22 before sacrificing the mice on Day 25 (3 injections).FIGS. 9F and 9G : GAPDH qPCR and representative Western blot of mice injected with RVG-exosome encapsulated siRNA (150 μg) on 2separate occasions exosomes 3 days before sacrifice and cortical sections were assayed with BACE-1 qPCR (FIG. 9I ), BACE-1 Western blot (FIG. 9H ) and, β-amyloid 1-42 ELISA (FIG. 9J ). All qPCR was normalised to 18S RNA levels. * indicates p<0.05 vs. untreated control. 3 mice were injected in each sample group and all error bars reflect standard deviation (n=3). - The present invention is directed to exosomes, and their use as gene delivery vehicles. Exosomes are small membrane-bound vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Thus, the present application is directed to a composition comprising such exosomes. Typically, the exosomes are between 30 and 100 nm in diameter but can include membrane particles of similar origin up to 200 nm. Exosomes as used herein refers to nanoparticles of endosomal origin that are secreted from multivesicular bodies.
- Exosomes are produced by many different types of cells including immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells. Exosomes are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells and tumour cells. Exosomes for use in accordance with the present application can be derived from any suitable cell, including the cells identified above. Exosomes have also been isolated from physiological fluids, such as plasma, urine, amniotic fluid and malignant effusions.
- In a preferred aspect of the present invention, exosomes are derived from DCs, preferably immature DCs. Exosomes produced from immature DCs do not express MHC-II, MHC-I or CD86. As such, such exosomes do not stimulate naïve T cells to a significant extent and are unable to induce a response in a mixed lymphocyte reaction. Thus exosomes produced from immature dendritic cells are ideal candidates for use in delivery of genetic material, particularly for in vivo use, for example, in gene therapy.
- Thus, in accordance with the first aspect of the present invention, exosomes derived from dendritic cells are provided for use in in vivo delivery of genetic material.
- In an alternative aspect of the present invention, exosomes can be obtained from any autologous patient-derived, heterologous haplotype-matched or heterologous stem cells so to reduce or avoid the generation of an immune response in a patient to whom the exosomes are delivered. Any exosome-producing cell can be utilized for this specific purpose.
- As outlined above, exosomes are produced by many different types of cell and have also been isolated from physiological fluids. Thus, in accordance with the present invention, exosomes can be obtained from any suitable cell type as discussed above, or by isolation from physiological fluids. Typically, the methods of the present invention comprise isolation of the exosomes from cell culture medium or tissue supernatant.
- Exosomes produced from cells can be collected from the culture medium by any suitable method. Typically a preparation of exosomes can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods. For example, exosomes can be prepared by differential centrifugation, that is low speed (<20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet exosomes, size filtration with appropriate filters (for example, 0.22 μm filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
- In accordance with the present invention, the exosomes are loaded with exogenous genetic material. In particular, in accordance with the present invention, exosomes are prepared and then loaded with the desired genetic material for delivery.
- Suitable genetic material for delivery includes exogenous DNA plasmid and siRNA. Suitable genetic material also includes modified oligonucleotides and other RNA interference effector moieties such as miRNA and shRNA. In accordance with one aspect of the present invention, the genetic material loaded into the exosome is not genetic material that is typically associated with the exosomes, for example, the nucleic acid is preferably not an mRNA or a miRNA which is incorporated into an exosome on its production from a cell. In particular, the present invention is concerned with the ability to load genetic material into an exosome preparation that has already been isolated from cells. Thus exogenous genetic material refers to genetic material inclusive of nucleic acids that is not normally associated with exosomes. In particularly preferred embodiments, the nucleic acid material is plasmid DNA or other nucleic acids such as siRNA and modified oligonucleotides which are not typically found in exosomes.
- Nucleic acids for incorporation into the exosomes may be single or double stranded. Single-stranded nucleic acids include those with phosphodiester, 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, and/or phosphorothioate backbone chemistry. Typically double-stranded nucleic acids are introduced including for example plasmid DNA and small interfering RNAs (siRNAs).
- The genetic material to be loaded into the exosomes is chosen on the basis of the desired effect of that genetic material on the cell into which it is intended to be delivered and the mechanism by which that effect is to be carried out. For example, the nucleic acid may be useful in gene therapy, for example in order to express a desired gene in a cell or group of cells. Such nucleic acid is typically in the form of plasmid DNA or viral vector encoding the desired gene and operatively linked to appropriate regulatory sequences such as promoters, enhancers and the like such that the plasmid DNA is expressed once it has been delivered to the cells to be treated. Examples of diseases susceptible to gene therapy include haemophilia B (Factor IX), cystic fibrosis (CTFR) and spinal muscular atrophy (SMN-1).
- Nucleic acid can also be used for example in immunisation to express one or more antigens against which it is desired to produce an immune response. Thus, the nucleic acid to be loaded into the exosome can encode one or more antigens against which is desired to produce an immune response, including but not limited to tumour antigens, antigens from pathogens such as viral, bacterial or fungal pathogens.
- Nucleic acid can also be used in gene silencing. Such gene silencing may be useful in therapy to switch off aberrant gene expression or in animal model studies to create single or more genetic knock outs. Typically such nucleic acid is provided in the form of siRNAs. For example, RNAi molecules including siRNAs can be used to knock down DMPK with multiple CUG repeats in muscle cells for treatment of myotonic dystrophy. In other examples, plasmids expressing shRNA that reduces the mutant Huntington gene (htt) responsible for Huntington's disease can be delivered with neuron specific exosomes. Other target genes include BACE-1 for the treatment of Alzheimer's disease. Some cancer genes may also be targeted with siRNA or shRNAs, such as ras, c-myc and VEGFR-2. Brain targeted siRNA loaded exosomes may be particularly useful in the silencing of BACE-1 in Alzheimer's disease, silencing of alpha-synuclein in Parkinson's disease, silencing of htt in Huntingdon's disease and silencing of neuronal caspase-3 used in the treatment of stroke to reduce ischaemic damage.
- Antisense modified oligonucleotides including 2′-O-Me compounds and PNA can be used. For example, such oligonucleotides can be designed to induce exon-skipping for example the mutant dystrophin gene can be delivered to muscle cells for the treatment of Duchenne Muscular Dystrophy, antisense oligonucleotides which inhibit hairpin loops, for example in the treatment of myotonic dystrophy and trans-splicing oligonucleotides, for example for the treatment of spinal muscular atrophy.
- The exogenous genetic material can be introduced into the exosomes by a number of different techniques. In particularly preferred embodiments of the invention, the exosomes are loaded by electroporation or the use of a transfection reagent. The present inventors have identified that despite the small size of exosomes, it is still possible to use electroporation to load the exosomes with the exogenous genetic material. This is surprising in view of the small size of the exosomes compared to cells. Extrapolation of the voltages used for electroporation of cells to take into account the size of the exosomes would suggest that excessively high voltages would be required for electroporation of exosomes. Surprisingly however, the present inventors have identified that it is possible to use electroporation to load exosomes with plasmid DNA and siRNA. Typical voltages are in the range of 20V/cm to 1000V/cm, such as 20V/cm to 100V/cm with capacitance typically between 25 μF and 250 μF, such as between 25 μF and 125 μF.
- In an alternative aspect of the present invention, the inventors have also identified that it is possible to load exosomes using transfection agents. Despite the small size of the exosomes, conventional transfection agents can be used for transfection of exosomes with genetic material. Preferred transfection reagents for use in accordance with the present invention include cationic liposomes.
- The present invention also relates to the targeting of exosomes to a desired cell type or tissue. This targeting is achieved by expressing on the surface of the exosome a targeting moiety which binds to a cell surface moiety expressed on the surface of the cell to be targeted. Typically the targeting moiety is a peptide which is expressed as a fusion protein with a transmembrane protein typically expressed on the surface of the exosome.
- In more detail, the exosomes can be targeted to particular cell types or tissues by expressing on their surface a targeting moiety such as a peptide. Suitable peptides are those which bind to cell surface moieties such as receptors or their ligands found on the cell surface of the cell to be targeted. Examples of suitable targeting moieties are short peptides, scFv and complete proteins, so long as the targeting moiety can be expressed on the surface of the exosome and does not interfere with insertion of the membrane protein into the exosome. Typically the targeting peptide is heterologous to the transmembrane exosomal protein. Peptide targeting moieties may typically be less than 100 amino acids in length, for example less than 50 amino acids in length, less than 30 amino acids in length, to a minimum length of 10, 5 or 3 amino acids.
- Targeting moieties can be selected to target particular tissue types such as muscle, brain, liver, pancreas and lung for example, or to target a diseased tissue such as a tumour. In a particularly preferred embodiment of the present invention, the exosomes are targeted to brain tissue.
- Specific examples of targeting moieties include muscle specific peptide, discovered by phage display, [33] to target skeletal muscle, a 29 amino acid fragment of Rabies virus glycoprotein that binds to the acetylcholine receptor [36] or a fragment of neural growth factor that targets its receptor [37] to target neurons and secretin peptide that binds to the secretin receptor can be used to target biliary and pancreatic epithelia [38]. As an alternative, immunoglobulins and their derivatives, including scFv antibody fragments can also be expressed as a fusion protein to target specific antigens, such as VEGFR for cancer gene therapy. As an alternative, natural ligands for receptors can be expressed as fusion proteins to confer specificity, such as NGF which binds NGFR and confers neuron-specific targeting.
- The peptide targeting moiety is expressed on the surface of the exosome by expressing it as a fusion protein with an exosomal transmembrane protein. A number of proteins are known to be associated with exosomes; that is they are incorporated into the exosome as it is formed. The preferred proteins for use in accordance with the present invention are those which are transmembrane proteins. Examples include but are not limited to Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3, CD2, CD36, CD40, CD40L, CD41a, CD44, CD45, ICAM-1, Integrin alpha4, L1CAM, LFA-1, Mac-1 alpha and beta, Vti-1A and B, CD3 epsilon and zeta, CD9, CD18, CD37, CD53, CD63, CD81, CD82, CXCR4, FcR, GluR2/3, HLA-DM (MHC II), immunoglobulins, MHC-I or MHC-II components, TCR beta and tetraspanins. In particularly preferred embodiments of the present invention, the transmembrane protein is selected from Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3. In a particularly preferred embodiment the transmembrane protein is Lamp-2. The sequence of Lamp-2 is set out in
SEQ ID No 1. - The following section relates to general features of all polypeptides of the invention, and in particular to variations, alterations, modifications or derivatisations of amino acid sequence which are included within the polypeptides of the invention. It will be understood that such variations, alterations, modifications or derivatisations of polypeptides as are described herein are subject to the requirement that the polypeptides retain any further required activity or characteristic as may be specified subsequent sections of this disclosure.
- Variants of polypeptides of the invention may be defined by particular levels of amino acid identity which are described in more detail in subsequent sections of this disclosure. Amino acid identity may be calculated using any suitable algorithm. For example the PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.
- The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. Alternatively, the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, 387-395).
- It will be understood that variants of polypeptides of the invention also includes substitution variants. Substitution variants preferably involve the replacement of one or more amino acids with the same number of amino acids and making conservative amino acid substitutions. For example, an amino acid may be substituted with an alternative amino acid having similar properties, for example, another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid or another aliphatic amino acid. Some properties of the 20 main amino acids which can be used to select suitable substituents are as follows:
-
Ala aliphatic, hydrophobic, neutral Cys polar, hydrophobic, neutral Asp polar, hydrophilic, charged (−) Glu polar, hydrophilic, charged (−) Phe aromatic, hydrophobic, neutral Gly aliphatic, neutral His aromatic, polar, hydrophilic, charged (+) Ile aliphatic, hydrophobic, neutral Lys polar, hydrophilic, charged (+) Leu aliphatic, hydrophobic, neutral Met hydrophobic, neutral Asn polar, hydrophilic, neutral Pro hydrophobic, neutral Gln polar, hydrophilic, neutral Arg polar, hydrophilic, charged (+) Ser polar, hydrophilic, neutral Thr polar, hydrophilic, neutral Val aliphatic, hydrophobic, neutral Trp aromatic, hydrophobic, neutral Tyr aromatic, polar, hydrophobic - The amino acid sequence of polypeptides for use in the invention may be modified to include non-naturally occurring chemistries or to increase the stability and targeting specificity of the compound. When the polypeptides are produced by synthetic means, such amino acids may be introduced during production. The polypeptides may also be modified following either synthetic or recombinant production.
- A number of side chain modifications are known in the art and may be made to the side chains of the polypeptides, subject to the polypeptides retaining any further required activity or characteristic as may be specified herein.
- Variant polypeptides as described in this section are those for which the amino acid sequence varies from that in SEQ ID NO: 1, but which retain the ability to be inserted into the membrane of an exosome.
- The variant sequences typically differ by at least 1, 2, 3, 5, 10, 20, 30, 50, 100 or more mutations (which may be substitutions, deletions or insertions of amino acids). For example, from 1 to 100, 2 to 50, 3 to 30 or 5 to 20 amino acid substitutions, deletions or insertions may be made, provided the modified polypeptide is inserted into the membrane of an exosome.
- Typically, polypeptides which are variants of Lamp-2 have more than about 50%, 55% or 65% identity, preferably at least 70%, at least 80%, at least 90% and particularly preferably at least 95%, at least 97% or at least 99% identity, with the amino acid sequence of SEQ ID NO: 1. The identity of variants of SEQ ID NO: 1 may be measured over a region of at least 30, 50, 100, 200, 250, 300, 350 or more contiguous amino acids of the sequence shown in SEQ ID NO: 1, or more preferably over the full length of SEQ ID NO: 1, excluding the signal sequence.
- The fragment of the Lamp-2 polypeptide used in the invention is typically at least 55 amino acids, 100, 150, 200, or 250 amino acids in length.
- The exosomal transmembrane protein is modified to incorporate a targeting moiety. Thus the exosomal transmembrane protein is expressed as a fusion protein comprising the targeting moiety. The targeting moiety is incorporated into the transmembrane protein such that it is positioned in the portion of the transmembrane protein present on the surface of the exosomes. In a preferred aspect of the present invention, the exosomal transmembrane protein is Lamp-2 and the targeting moiety is expressed as a fusion protein, wherein the targeting moiety is present near the N-terminus of Lamp-2 protein for example within 30, or within 20 amino acids of the Lamp-2 N terminal amino acid, not including the signal sequence.
- Spacer or linker sequences may be provided between the targeting moiety and the remainder of the transmembrane protein for example to avoid interference from the targeting moiety in the folding of the transmembrane protein.
- Linker or spacer sequences are typically 1 to 10 amino acids in length, typically 1 to 8 amino acids in length such as 2, 3 or 4 amino acids in length. Suitable amino acids for incorporation in linkers are alanine, arginine, serine or glycine. Suitable linkers include Ala-Arg and Ser-Gly-Gly.
- In a particularly preferred aspect of the present invention, the transmembrane protein is Lamp-2 and the targeting moiety is present at or near the N-terminus of the protein, separated from Lamp-2 with linker sequences.
- In the practice of the present invention, the targeting moiety is introduced into the exosome by expressing the fusion protein comprising the targeting moiety and exosomal transmembrane protein within a cell used to produce the exosomes. Expression of this fusion protein in the cell, allows for the fusion protein to be incorporated into the exosome as it is produced from the cell.
- For example, a polynucleotide construct such as a DNA plasmid, which expressed the fusion protein is transfected into the cell. Any suitable method can be used for introduction of the polynucleotide construct into the cell. The polynucleotide construct includes suitable promoter sequences so that the encoded fusion protein is expressed in the cell. Signal peptide sequences are also included so that the protein is incorporated into the membrane of the endoplasmic reticulum as it is produced. The membrane protein is then subsequently exported to the exosomal/lysomal compartment before incorporation into the exosome. The signal sequence is typically a signal peptide sequence for an exosomal transmembrane protein. For example the signal peptide sequence is preferably derived from Lamp-2, for example as shown in the Examples.
- Preferred cells for production of exosomes are discussed in more detail above. Typically a preferred cell, such as an immature dendritic cells is transfected with a polynucleotide construct as described above, such that the fusion protein of the invention is expressed in the cell. Exosomes produced by the cell can then be collected. Such exosomes have the fusion protein inserted into the membrane such that the exosomes are targeted to the desired tissue or cell type through the targeting moiety.
- Exosomes produced from cells can be collected from the culture medium by any suitable method. Typically a preparation of exosomes can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods. For example, exosomes can be prepared by differential centrifugation, that is low speed (<20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet exosomes, size filtration with appropriate filters (for example, 0.22 μm filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
- In accordance with a preferred aspect of the present invention, the targeted exosomes are loaded with exogenous genetic material. In particular, in accordance with the present invention, exosomes are prepared with a targeting moiety as described herein and then loaded with the desired genetic material for delivery or described above.
- In other embodiments of the invention, a specific targeting moiety does not need to be included in the exosome. For example, exosomes may be administered directly to the site where therapy is required. Alternatively, for example, where exosomes contain genetic material encoding immunogens, direct targeting to a specific site may not be required and delivery, for example, intradermal or muscular delivery may be sufficient to generate the desired immune response without targeting exosomes to any specific cell type.
- In some embodiments of the invention, no targeting moiety is included on the surface of the exosomes. However, the exosomes are selected such that they are more likely to target a specific tissue type. For example, exosomes derived from different cells may have natural affinities for specific cell subtypes as required by their physiological function such as the well-established affinity of mature dendritic cell-derived exosomes to T-cells. This affinity may be utilized to specifically deliver above-mentioned cargo to a tissue.
- The constructs of the invention may be administered by any suitable means.
- Administration to a human or animal subject may be selected from parenteral, intramuscular, intracerebral, intravascular, subcutaneous, or transdermal administration. Typically the method of delivery is by injection. Preferably the injection is intramuscular or intravascular (e.g. intravenous). A physician will be able to determine the required route of administration for each particular patient.
- The constructs are preferably delivered as a composition. The composition may be formulated for parenteral, intramuscular, intracerebral, intravascular (including intravenous), subcutaneous, or transdermal administration. Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. The constructs of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharmaceutically acceptable carriers or excipients and the like in addition to the exosomes.
- A “pharmaceutically acceptable carrier” (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc); fillers (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g. magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g. starch, sodium starch glycolate, etc.); or wetting agents (e.g. sodium lauryl sulphate, etc.).
- The compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions provided herein.
- A therapeutically effective amount of composition is administered. The dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. Optimum dosages may vary depending on the relative potency of individual constructs, and can generally be estimated based on EC50s found to be effective in vitro and in in vivo animal models. In general, dosage is from 0.01 mg/kg to 100 mg per kg of body weight. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to 10 mg/kg of body weight, according to the potency of the specific construct, the age, weight and condition of the subject to be treated, the severity of the disease and the frequency and route of administration. Different dosages of the construct may be administered depending on whether administration is by intramuscular injection or systemic (intravenous or subcutaneous) injection. Preferably, the dose of a single intramuscular injection is in the range of about 5 to 20 μg. Preferably, the dose of single or multiple systemic injections is in the range of 10 to 100 mg/kg of body weight.
- Due to construct clearance (and breakdown of any targeted molecule), the patient may have to be treated repeatedly, for example once or more daily, weekly, monthly or yearly. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the construct in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy, wherein the construct is administered in maintenance doses, ranging from 0.01 mg/kg to 100 mg per kg of body weight, once or more daily, to once every 20 years.
- The invention is hereinafter described in more detail with reference to the following Examples.
- We aimed to determine if exosomes can be reproducibly produced from dendritic cells harvested from murine bone marrow. Using a protocol modified from Quah et al. [28], bone marrow cells were harvested from femurs of C57BL/6 mice, dissociated with gentle mashing and cultured in the presence of DC medium (refer materials and methods) with 10 ng/ml GM-CSF, which stimulates proliferation of progenitor cells. Non-adherent cells were removed after 4 days, leaving dendritic cells in culture. After 7 days, GM-CSF is removed and fresh DC medium without GM-CSF is added to isolate exosomes. Exosomes are harvested daily over the next 2 days by centrifugation of culture supernatant, first at 10,000 g to remove cellular debris, then at 120,000 g to pellet exosomes. The exosomes are then resuspended in an appropriate amount of 0.1M ammonium acetate buffer.
- The exosomes produced were consistent and physically homogenous, with a size distribution peaking at 80 nm in diameter as determined by electron microscopy (
FIG. 1A ), Western with an antibody against an exosomal protein (Lamp2b) (FIG. 1B ) and dynamic light scattering (FIG. 1C ). - Transfection of a targeting ligand is required to alter the specificity of the exosomes in order to effectively target desired cell types.
FIG. 2A illustrates how a targeting ligand is inserted into Lamp2b. As it is a type I membrane protein with an N-terminus predicted to protrude out of the exosome, the targeting ligand needs to be attached to the N-terminus after the signal peptide. The signal peptide is required for membrane insertion but is cleaved off in the mature protein. In addition, the targeting peptide is flanked by linkers (Ala-Arg-{Targeting Peptide}-Ser-Gly-Gly) to prevent the targeting peptide from influencing the folding of the Lamp2b protein. Ultimately, the targeting peptide should be located on the external surface of the exosomes, hence conferring targeting capabilities to the exosomes Three different peptides—the neuron-specific rabies viral glycoprotein (RVG) peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG (SEQ ID No: 6)) [32], a muscle-specific peptide (MSP) identified by in vivo phage display (ASSLNIA) (SEQ ID No: 9) [33], and a FLAG epitope—were separately cloned into Lamp2b and transfected into thedendritic cells 4 days before exosome purification. Both MSP and RVG were selected for organ specificity while the FLAG epitope in the targeting ligand site was used to differentiated modified Lamp2b and unmodified exogenous Lamp2b. A major hindrance to the ability to express targeting ligands on the surface of exosomes is that primary dendritic cells are difficult to transfect and can potentially differentiate after transfection. Infection with viral vectors is not ideal either as dendritic cells are likely to be activated by the virus [30], hence producing immunostimulatory molecules that will be incorporated into the resultant exosomes. Hence, a number of transfection reagents were tested and Mints Bio's TransIT-LT1 reagent was selected as it appeared to efficiently transduce dendritic cells, with a 49900 fold increase in eGFP mRNA normalized to murine GAPDH over the addition by pEGFP-NAD, an eGFP-expressing plasmid, alone without transfection reagents. More importantly, this transfection does not appear to significantly activate dendritic cells based on observation of cell morphology. Immature dendritic cells are compact rounded cells with low surface area-to-volume ratios while activated dendritic cells have characteristic dendritic extensions and large surface area-to-volume ratios [31]. - Meanwhile, Western blot against the FLAG ligand clearly demonstrates that FLAG-Lamp2b (115 kDa) is expressed in dendritic cells and corresponding exosomes after transfection of pLamp2b-FLAG but not in normal cells and exosomes (
FIG. 2B ). Expression of MSP-Lamp2b and RVG-Lamp2b was verified with qRT-PCR of dendritic cells transfected with pLamp2b-MSP and pLamp2b-RVG using specific primers for the MSP and RVG sequences (FIG. 2C ). - As the topology of Lamp2b on exosomes was unknown, a pulldown assay with anti-FLAG beads was designed to establish the orientation of the targeting epitope. Anti-FLAG antibody or a non-specific antibody (Ago1) was bound to protein-A Sepharose beads (Sigma). These beads were then incubated with unmodified or FLAG-exosomes before 3 washes to remove non-binders. If the FLAG epitope was exclusively internal and inaccessible to the antibody, neither unmodified nor FLAG-exosomes should be retained on the beads; if the FLAG epitope was external, FLAG-exosomes would be retained but not unmodified exosomes. Following pulldown, the retained exosomes were denatured and detected by Western blot against LAMP-1, another exosomal protein that serves as a marker for the presence of exosomes. Western blot for Lamp1, another exosome-specific protein, showed increased retention of FLAG-exosomes by anti-FLAG beads but not by control anti-Ago-1 (non-specific) beads (
FIG. 2D ). This result demonstrates that the targeting moiety is localized to the external exosomal surface and validating its targeting potential. These modifications do not appear to affect the physical properties of the modified exosomes based on dynamic light scattering of MSP-exosomes (FIG. 2E ). - Transfection of dendritic cells was performed with 5 μg of pEGFP-NAD or pLamp2b derivatives and 5 μl of TransIT LT1 transfection reagent (Minis Bio) in a 6-well plate with 106 cells on
Day 4 after harvesting. Medium is changed on Day 7 and exosomes are isolated from culture supernatant on Day 8. - Protocol: Transfection and Electroporation with Exosomes and DNase Protection Assay
- For the following experiments, an EGFP-expressing plasmid, pEGFP-NAD, was used as DNA cargo, Cy5-labeled anti-GAPDH siRNA and unlabelled anti-mouse cyclophilin B were used as RNA cargo and a Cy3-labeled 2′-OMe oligonucleotide and a Cy3-labelled morpholino designed for exon skipping in mdx mice (gift from Haifang Yin) were used.
- Circular and linearized pEGFP-NAD were electroporated with exosomes and then exposed to DNase I for 10 minutes. If the DNA was successfully loaded in to the exosomes, the DNase will be unable to digest the DNA as it is unable to access the interior of the exosomes; conversely, if the DNA was not located within the exosomes, the presence of DNase will result in DNA degradation and the loss of a plasmid signal. When a DNase protection assay was performed on plasmid DNA, electroporation with exosomes appear to protect circular DNA plasmid from degradation but not linear DNA (
FIG. 3A ) and that lower capacitance appears to increase uptake of DNA into exosomes (FIG. 3B ). To exclude the possibility that factors released from the exosomes by electroporation inhibited DNase activity, DNA was added to pre-electroporated exosomes as a control. In addition to that, it appears the super-coiled fraction is preferentially protected (higher band). This may be because exosomes are themselves 20-30 nm yet an open circular plasmid 1868nt in length can be over 100 nm in diameter, while a supercoiled plasmid is more compact and takes up significant less volume [34], hence supercoiled plasmids are preferentially protected. - The difficulty of coming up with a suitable electroporation protocol is highlighted by inconsistent results and often low level of protection even when successful (results not shown). Artificially condensing DNA with spermine resulted in reduced DNase protection (results not shown), possibly because the concentration of spermine used is extremely critical in producing condensates of the right size [35]. Too little and no condensation occurs, but too much and large aggregates form, which may be the reason why the addition of spermine actually decreased the levels of DNase protection.
- A separate approach utilizing transfection instead of electroporation resulted in significant DNase protection for open circular plasmids. 1 μg of the pEGFP-NAD plasmid was mixed with 1 μl of the transfection reagent, exosomes (3 μg) and topped up to 100 μl with DMEM. The solution was incubated for 3 hours at 37° C. and then subjected to DNase treatment for 10 minutes at 37° C. with the addition of 1 μl of RQ DNase I (Promega) and 10 μl of RQ DNase buffer. The DNase was inactivated by 10 μl of STOP buffer (Promega) before the DNase protection assay or the direct addition of the entire solution to Neuro2A or C2C12 cells in a 24-well format. Three different transfection reagents (1:Lipofectamine 2000 (Invitrogen); 2:TransIT LT1 (Minis Bio) 3: TurboFect (Fermantas)) were used to deliver open circular pEGFP-NAD into exosomes and preliminary results suggest that
Reagent 3 resulted in significant DNase protection (FIG. 3D ), suggesting that transfection reagents can be used to load genetic cargo into exosomes. The control experiments with transfection reagent alone seem to indicate the transfection reagent does not confer protection by itself (FIG. 3C ). Despite the fact that open circular plasmids are predicted to be too large for exosomes, the addition of transfection reagent may serve to condense the plasmids as well as provide additional hydrophobic molecules to increase the size of the exosomes. - For the DNase protection Assay, 20 μl of the electroporated solution was added to 70 μl of distilled water, 10 μl of RQ DNase Buffer and 1 μl RQ DNase I (Promega) and incubated at 37° C. for 10 min before inhibiting the reaction with 10 μl of STOP buffer. 10 μl of each sample was run on each lane in a 0.8% agarose TAE gel.
- Protocol: Delivery of Genetic Material by Exosomes into Neuro2A and C2C12 Cells
- Since exosomes were found to take up DNA plasmids readily upon electroporation and transfection, we hypothesized that exosomes loaded with pEGFP-NAD would be able to transfect cells in vitro. We added transfection reagent 3 (
FIG. 3C ) to pEGFP-NAD without exosomes, with wild type exosomes, or with exosomes harvested from dendritic cells transfected with pLamp2b-RVG (RVG-exosomes) or pLamp2b-MSP (MSP-exosomes) and DNase treated the mixture after incubation, including the sample with pEGFP-NAD and transfection reagent alone. The cells were then transfected directly with the mixture for 2 days and results suggest that both at the RNA level through qRT-PCR (FIGS. 4B and 4C ) and at the protein level through GFP fluorescence (FIG. 4A ), exosomes efficiently transferred pEGFP-NAD into target cells. In addition, results suggest that RVG and MSP peptides improve the uptake of pEGFP-NAD by increasing affinity to Neuro2A and C2C12 cells exclusively and this phenomenon is cell type-dependent. - Given that exosomes were able to take up DNA plasmids and contain RNA naturally [26], siRNAs should also be readily taken up by exosomes. We hypothesized that exosomes would also be able to deliver siRNAs. Hence, a well characterized Cy5-labeled siRNA against GAPDH (Ambion) was electroporated into wild type, RVG- and MSP-exosomes and applied directly to Neuro2A and C2C12 cells. The cells were then imaged after 2 days and showed higher fluorescence when compared to control cells treated with siRNA and unelectroporated exosomes alone (
FIGS. 5A and 5B ). Similar protocols were followed for the transfection of cells with exosomes and qRT-PCR of GAPDH normalised to 18S RNA (FIGS. 5C and 5D ) demonstrated significant knockdown in targeted exosomes compared to controls after 2 days, suggesting that the siRNAs were released into the cytoplasm after transfection to actively repress the endogenous target and that the targeting moiety effectively delivered the siRNA to the desired cell type i.e. neuron-specific RVG to neuronal Neuro2A cells and muscle specific MSP to C2C12 myoblasts. This knockdown was further confirmed with Western blot of the GAPDH protein (FIGS. 5E and 5F ). - As further evidence of specific delivery, a second siRNA against murine cyclophilin B (PPIB) (Ambion) was also transfected similarly and demonstrated similar patterns of knockdown (
FIG. 6 ) as measured by qPCR and Western blots. - In order to quantify the loading efficiency of different electroporation protocols, 3 μg of murine PPIB siRNA labelled with a Cy3 and a Cy5 fluorophore on either strand was mixed with 3 μg p.e. of RVG-exosomes, added to an electroporation buffer based on Eppendorf Hypoosmolar Buffer and electroporated on a Biorad GenePulsar II in a 4 mm cuvette. The mixture was then diluted with PBS and spun down at 120,000 g for 60 minutes to purify the exosomes. The resultant pellet was resuspended in 100 μl of double distilled water, which is predicted to lyse the exosomes via osmotic pressure and release the encapsulated siRNA within. The siRNA content was then measured with a fluorescence plate reader with 560 nm excitation and 610 nm emission and the retained siRNA quantified against a standard curve of pure siRNA in water. As shown in
FIG. 7 , over 20% of initial siRNA (0.73 μg) was retained after electroporation at 400V and 125 μF, the optimum electroporation setting. Furthermore, concentrating the mixture by decreasing the amount of electroporation buffer appeared to increase the loading up to a certain level. - Finally, transfection of labeled 2′-OMe oligonucleotide (100 pmoles) and PMO (100 pmoles) were attempted with normal exosomes in C2C12 cells and imaged a day after application. Of the two types of small oligonucleotide species, 2′-OMe oligonucleotide appears to be effectively delivered into C2C12 cells (
FIG. 8A ) while morpholino (PMO) delivery does not appear to be improved by exosome-mediated delivery with unmodified exosomes (FIG. 8B ). From this experiment, we believe it is possible for us to load a variety of unnatural oligonucleotides into the exosome for delivery, including 2′-OMe, morpholino, thio-nucleotides, chemically modified siRNAs and peptide nucleic acids. - Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich UK and all enzymes used were obtained from New England Biolabs.
- Dendritic cells were cultured in DC medium (DMEM Glutamax, 10% FBS, non-essential amino acids # and antibiotics). C2C12 cells were cultured in DMEM Glutamax supplemented with 20% FBS and antibiotics. Neuro2A cells were cultured in EMEM supplemented with 10% FBS. All cells were incubated at 37° C. in 5% CO2.
- Lamp2b was cloned with cDNA from C2C12 cells and XhoI and BspEI restriction sites were inserted after the signal peptide sequence together with glycine linkers. The full construct was then cloned downstream of the CMV promoter with NheI and HindIII restriction sites into a pEGFP-C1 vector, removing the eGFP in the process. Primers designed to encode RVG [32], MSP [33] and FLAG tag were used to introduce the targeting ligands between XhoI and BspEI at the N-terminus of Lamp2b (
FIG. 6A ). Primer sequences for the peptides were -
RVG(YTIWMPENPRPGTPCDIFTNSRGKRASNG) (SEQ ID No: 6): Forward (SEQ ID No: 7) 5′-tcgatacaccatttggatgcccgagaatccgagaccagggacaccttgtgacatttttaccaatagcagagg gaagagagcatccaacgggt-3′ Reverse (SEQ ID No: 8) 5′-ccggacccgttggatgctctcttccctctgctattggtaaaaatgtcacaaggtgtccctggtctcggattctc gggcatccaaatggtgta-3′ MSP(ASSLNIA) (SEQ ID No: 9): Forward (SEQ ID No: 10) 5′-tcgagccagcagcctgaacatcgcct-3′ Reverse (SEQ ID No: 11) 5′-ccggaggcgatgttcaggctgctggc-3′ FLAG (DYKDDDDK): (SEQ ID No: 12) Forward (SEQ ID No: 13) 5′-tcgagattacaaggatgacgatgacaagt-3′ Reverse (SEQ ID No: 14) 5′-ccggacttgtcatcgtcatccttgtaatc-3′ Murine Lysosome-associated membrane glycoprotein 2 (Lamp 2) isoform 2 Unmodified amino acid sequence (SEQ ID NO 1) MCLSPVKGAKLILIFLFLGAVQSNALIVNLTDSKGTCLYAEWEMNFTITYETTNQTN <-- Signal peptide --> KTITIAVPDKATHDGSSCGDDRNSAKIMIQFGFAVSWAVNFTKEASHYSIHDIVLSY NTSDSTVFPGAVAKGVHTVKNPENFKVPLDVIFKCNSVLTYNLTPVVQKYWGIHLQA FVQNGTVSKNEQVCEEDQTPTTVAPIIHTTAPSTTTTLTPTSTPTPTPTPTPTVGNY <-- hinge region --> SIRNGNTTCLLATMGLQLNITEEKVPFIFNINPATTNFTGSCQPQSAQLRLNNSQIK YLDFIFAVKNEKRFYLKEVNVYMYLANGSAFNISNKNLSFWDAPLGSSYMCNKEQVL SVSRAFQINTFNLKVQPFNVTKGQYSTAQECSLDDDTILIPIIVGAGLSGLIIVIVI <-- Transmembrane AYLIGRRKTYAGYQTL --> Modified amino acid sequence (added sequence underlined) MCLSPVKGAKLILIFLFLGAVQSNALIVNLTDSKGTQLY A <peptide tag> GG AEWEMNFTITYETTNQTNKTITIAVPDKATHDGSSCGDDRNSAKIMIQFGFA... (“depicts residues 1-39 of SEQ ID NO: 1, followed by peptide tag, and residues 4-91 of SEQ ID NO: 1) Unmodified nucleotide sequence (SEQ ID No: 2) atgtgcctctctccggttaaaggcgcaaagctcatcctgatctttctgttcctaggagccgttc agtccaatgcattgatagttaatttgacagattcaaagggtacttgcctttatgcagaatggga gatgaatttcacaataacatatgaaactacaaaccaaaccaataaaactataaccattgcagta cctgacaaggcgacacacgatggaagcagttgtggggatgaccggaatagtgccaaaataatga tacaatttggattcgctgtctcttgggctgtgaattttaccaaggaagcatctcattattcaat tcatgacatcgtgctttcctacaacactagtgatagcacagtatttcctggtgctgtagctaaa ggagttcatactgttaaaaatcctgagaatttcaaagttccattggatgtcatctttaagtgca atagtgttttaacttacaacctgactcctgtcgttcagaaatattggggtattcacctgcaagc ttttgtccaaaatggtacagtgagtaaaaatgaacaagtgtgtgaagaagaccaaactcccacc actgtggcacccatcattcacaccactgccccgtcgactacaactacactcactccaacttcaa cacccactccaactccaactccaactccaaccgttggaaactacagcattagaaatggcaatac tacctgtctgctggctaccatggggctgcagctgaacatcactgaggagaaggtgcctttcatt tttaacatcaaccctgccacaaccaacttcaccggcagctgtcaacctcaaagtgctcaactta ggctgaacaacagccaaattaagtatcttgactttatctttgctgtgaaaaatgaaaaacggtt ctatctgaaggaagtgaatgtctacatgtatttggctaatggctcagctttcaacatttccaac aagaaccttagcttctgggatgcccctctgggaagttcttatatgtgcaacaaagagcaggtgc tttctgtgtctagagcgtttcagatcaacacctttaacctaaaggtgcaaccttttaatgtgac aaaaggacagtattctacagcccaggagtgttcgctggatgatgacaccattctaataccaatt atagttggtgctggtctttcaggcttgattatcgttatagtgattgcttacctaattggcagaa gaaagacctatgctggatatcagactctgtaa Modified nucleotide sequence (added sequence in italics and restrictions sites used for cloning in underlined) (SEQ ID No: 25) atgtgcctctctccggttaaaggcgcaaagctcatcctgatctttctgttcctaggagccgttc agtccaatgcattgatagttaatttgacagattcaaagggtacttgcctttatG CTCGAG GTCA CA TCCGGAG GTgcagaatgggagatgaatttcacaataacatatgaaactacaaaccaaaccaa taaaactataaccattgcagtacctgacaaggcgacacacgatggaagcagtt... - Transfection of dendritic cells was performed with 5 μg of pEGFP-NAD or pLamp2b derivatives and 5 μl of TransIT LT1 transfection reagent (Minis Bio) in a 6-well plate with 106 cells on
Day 4 after harvesting and isolation of exosomes is done on Day 8. - Reverse Transcription qPCR
- Reverse transcription was performed with 500 ng of RNA and random primer using Precision Reverse Transcription Kit (Primer Design) as per manufacturer's instruction. qPCR experiments were performed on an ABI7000 thermal cycler in 20 μl reactions, with 0.5 nM of each primer and 2 μl of each cDNA preparation, using Precision qPCR Mastermix (Primer Design) as per manufacturer's instructions.
-
qPCR primer sequences Cyclophilin-B human Forward (SEQ ID No: 15) 5′-AAAGTCACCGTCAAGGTGTATTT-3′ Reverse (SEQ ID No: 16) 5′-TCACCGTAGATGCTCTTTCCTC-3′ GAPDH human Forward (SEQ ID No: 17) 5′-AAGGTGAAGGTCGGAGTCAA-3′ Reverse (SEQ ID No: 18) 5′-GAAGATGGTGATGGGATTTC-3′ GAPDH mouse Forward (SEQ ID No: 19) 5′-CAATGTGTCCGTCGTGGATCT-3′ Reverse (SEQ ID No: 20) 5′-TAGCCCAAGATGCCCTTCAGT-3′ eGFP Forward (SEQ ID No: 21) 5′-TCTTCAAGTCCGCCATGCC-3′ Reverse (SEQ ID No: 22) 5′-TGTCGCCCTCGAACTTCAC-3′ 18S Forward (SEQ ID No: 23) 5′-GTAACCCGTTGAACCCCATT-3′ Reverse (SEQ ID No: 24) 5′-CCATCCAATCGGTAGTAGCG-3′ Mouse cyclophilin B. Mm_PPIB_1_SG Quantitect Primer Assay (Qiagen) - Cell samples and exosomes were lysed in a 10 mM Tris pH 7.4 buffer containing 0.1% SDS, a protease inhibitor cocktail and DNase. Samples were separated on NuPAGE® Novex 4-12% Bis-Tris Gel (Invitrogen), and transferred to a PVDF membrane (Amersham Biosciences). The membrane was then blocked with 10% milk in PBS for 1 hour, incubated with primary antibody for 90 min at a dilution of 1:5000 for anti-Lamp2 antibody (Abcam), 1:10000 for anti-GAPDH (Abcam) and anti-cyclophilin B (Abcam). Membranes were incubated with HRP-conjugated secondary antibody 1:5000 dilution for 45 minutes at room temperature before film exposure. All steps were followed by 3 washes with PBST for 10 min each.
- Transfection and Electroporation with Exosomes and DNase Protection Assay
- 1 μg of the pEGFP-NAD plasmid was mixed with 1 μl of the transfection reagent, 3 of exosomes and topped up to 100 μl with DMEM. The solution was incubated for 3 hours at 37° C. and then subjected to DNase treatment for 10 minutes at 37° C. with the addition of 1 μl of RQ DNase I (Promega) and 10 μl of RQ DNase buffer. The DNase was inactivated by 10 μl of STOP buffer (Promega) before the direct addition of the entire solution to Neuro2A cells in a 24-well format.
- Exosomes were loaded to a protein concentration of 6 μg in 200 μl of electroporation buffer (1.15 mM potassium phosphate pH 7.2, 25 mM KCl, 21% Optiprep) and 2 μg of pEGFP-NAD or 100 pmol of cyclophilin siRNA was added, mixed and electroporated in a 4 mm cuvette. For the DNase protection Assay, 20 μl of the electroporated solution was added to 70 μl of distilled water, 10 μl of RQ DNase Buffer and 1 μl RQ DNase I (Promega) and incubated at 37° C. for 10 min before inhibiting the reaction with 10 μl of STOP buffer. 10 μl of each sample was run on each lane in a 0.8% agarose TAE gel.
- Transfection of Cells with Exosomes
- 100 ul (electroporation) or the entire mixture (transfection) was added to Neuro2A cells in complete medium. For siRNAs, the medium is changed after 24 hours. The cells were harvested 48 hours after addition of the exosomes.
- 20 μl of Protein-A Sepharose beads (Sigma P9424) were incubated overnight at 4° C. in 500 μl PBS and 2 mg/ml BSA. In the protocol, beads were pelleted during the steps by centrifugation at 100 g for 2 minutes at 4° C. The beads were subsequently washed 3 times with 1 ml PBS for 5 minutes each wash. 1 μl Rabbit anti-FLAG (Sigma F2555) or 1 μl of Rabbit anti-Ago1 (Upstate 07-599) was loaded onto the beads in 100 μl of PBS with 2 mg/ml BSA for 4 hours at 4° C. and the beads were subsequently washed 3 times as described above. Normal exosomes and FLAG-exosomes were spun at 200 g for 10 min to remove contaminating debris and added to the beads to a protein concentration of 10 μg/ml in 200 μl of PBS. After incubation, the beads were subsequently washed 3 times as described above, then eluted in 0.1% SDS and the entire supernatant was loaded onto a polyacrylamide gel. A Western blot against Lamp-1, an exosomal protein was used to detect the presence of exosomes pulled down by the antibodies.
- All experiments, unless otherwise stated, were all performed in triplicates. All error bars used in this report are standard deviations. Statistical analyses of the data were performed using SPSS program 16.0 by using the non-parametric Krusckal Wallis test followed by the Mann-Whitney U test.
- Exosome-Mediated Targeted Systemic Delivery of siRNA to the Brain
- Immunologically inert exosomes were harvested from murine bone marrow-derived dendritic cells and targeting moieties—muscle-specific peptide (MSP) and neuron-specific rabies viral glycoprotein (RVG), were genetically engineered onto Lamp2b, an exosomal membrane protein, to alter tissue specificity of these exosomes, as described above. To investigate the potential for exosome-mediated systemic siRNA delivery in vivo and characterize the tissue distribution, the ubiquitously highly-expressed housekeeping GAPDH gene was chosen as a target. We electroporated 150 μg of optimized GAPDH siRNA with 150 μg of either unmodified, RVG- or MSP-exosomes, then purified the exosomes by ultracentrifugation and removed unencapsulated siRNA in the supernatant. Exosomes were resuspended in 80 μl of 5% glucose before intravenous injection in C57BL/6 mice. Injection of naked siRNA (150 μg) resulted in detectable GAPDH silencing in the spleen, liver and kidney, corresponding to reported siRNA sequestration after tail vein delivery [42] (
FIG. 9A ). In contrast, exosome-encapsulated siRNAs appeared to have no natural affinity to these organs and were resistant to non-specific uptake. Systemic administration of unmodified exosomes did not induce GAPDH silencing in any organ analyzed (FIG. 9b ). Injection of MSP-exosomes produced a slight, but non-significant GAPDH silencing in brain and kidney (FIG. 9C ), whereas injection of RVG-exosomes resulted in significant knockdown of GAPDH mRNA in several brain regions (FIG. 9D ), a tissue expressing the target of RVG ligand—nicotinic acetylcholine receptors [32]. We also observed a non-significant decrease of GAPDH mRNA level inkidney 3 days after injection. Although in vivo tissue specificity was not seen with MSP-exosomes, the relatively weak targeting capabilities of MSP [43] and the abundance of muscle tissue may have resulted in much lower average siRNA concentration within muscle cells and hence, correspondingly lower gene knockdown. - We next investigated if re-administration of exosomes leads to decreased transgene delivery efficiency previously described in viruses [44, 45] and liposomes. We designed two different experiments to assess this question. First, we studied if pre-inoculating the animals with empty RVG-exosomes would reduce the efficacy of delivery. The animals were injected with empty RVG-exosomes at the
same dose FIGS. 9D and 9E ), demonstrating that targeted exosomes can be readministered multiple times without loss in delivery efficacy. Finally, to confirm the results, we injected three mice with two doses of RVG-exosomes containing GAPDH siRNA at the same concentration. Animals were injected 7 and 3 days before harvesting the tissues and GAPDH mRNA and protein knockdown were assessed in the brain. Knockdown was observed with GAPDH mRNA (50.2%±9.1%, p<0.05) and protein levels (19.6%±2.3%, not significant) in the cortex (FIGS. 9F and 9G ). These experiments validated the previous results and demonstrated that RVG-exosomes can be re-administered multiple times without loss of delivery efficacy allowing for long-term target silencing. - Given the success of knockdown with GAPDH, BACE-1, a key enzyme in the pathogenesis of Alzheimer's disease (AD), was targeted to evaluate the therapeutic potential of this technology. Previous studies in transgenic APP over-expressing [46, 47] and normal [48] mice suggested that BACE-1 is a strong candidate for anti-AD therapeutic intervention. We delivered two BACE-1 siRNAs, previously validated in vitro, to normal C57BL/6 mice. 150 μg of RVG-exosomes and 150 μg of each BACE-1 siRNA were electroporated, purified and resuspended in 5% glucose before delivery. Significant mRNA (72%±18%) and protein (60%±13%) knockdown in
cortex 3 days after administration (FIGS. 9H and 9I ). Moreover we demonstrated a decrease of 20% in the total content of β-amyloid 1-42, a main component of the amyloid plaques in the Alzheimer's pathology (FIG. 9J ). This result was comparable to the β-amyloid 1-40 decrease demonstrated in normal mice after intraventricular injection of BACE-1 inhibitors [48]. This experiment demonstrated the therapeutic potential of this technology, which is potentially ideally suited for long-term silencing of genes related with neurodegenerative diseases. - 1 Smith A J, Schlichtenbrede F C, Tschernutter M, Bainbridge J W, Thrasher A J, Ali R R (2003), AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa, Mol Ther 8(2):188-95.
- 2 Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P (2008), Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo, Mol Ther 16(6):1105-12.
- 3 White M D, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci G R (2008), Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease, Proc Natl Acad Sci USA 105(29):10238-43.
- 4 Reynolds A, Leake D, Boese Q, Scaringe S, Marshall W S, Khvorova A (2004), Rational siRNA design for RNA interference, Nat Biotechnol 22(3):326-30.
- 5 Takakura Y, Nishikawa M, Yamashita F, Hashida M (2001), Development of gene drug delivery systems based on pharmacokinetic studies, Eur J Pharm Sci 13(1):71-76.
- 6 Kawabata K, Takakura Y, Hashida M (1995), The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake, Pharm Res 12(6):825-30.
- 7 www.wiley.co.uk/genmed/clinical/Retrieved on 9 Sep. 2008.
- 8 Lowenstein P R, Mandel R J, Xiong W D, Kroeger K, Castro M G (2007), Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions, Curr Gene Ther 7(5):347-60.
- 9 Alexander I E, Cunningham S C, Logan G J, Christodoulou J (2008), Potential of AAV vectors in the treatment of metabolic disease, Gene Ther.; 15(11):831-9.
- 10 Hasbrouck N C, High K A (2008), AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects, Gene Ther 15(11):870-5.
- 11 Daniel R, Smith J A (2008), Integration site selection by retroviral vectors: molecular mechanism and clinical consequences, Hum Gene Ther 19(6):557-68.
- 12 Zhang J S, Liu F, Huang L (2005), Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity, Adv Drug Deliv Rev 57(5):689-98.
- 13 Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H (2005), Accelerated clearance of a second injection of PEGylated liposomes in mice, Int J Pharm 255:167-74.
- m Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. (2006), Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J Control Release 112:15-25.
- 15 Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H (2006), Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J Control Release 112:15-25.
- 16 Jiang H, Couto L B, Patarroyo-White S, Liu T, Nagy D, Vargas J A, et al (2006), Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood 108(10):3321-8.
- 17 Wang Z, Kuhr C S, Allen J M, Blankinship M, Gregorevic P, Chamberlain J S, et al (2007), Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression, Mol Ther 15(6):1160-6.
- 18 Li J Z, Li H, Hankins G R, Dunford B, Helm G A (2005), Local immunomodulation with CD4 and CD8 antibodies, but not cyclosporine A, improves osteogenesis induced by ADhBMP9 gene therapy, Gene Ther 12(16):1235-41.
- 19 Zaiss A K, Muruve D A (2005), Immune responses to adeno-associated viral vectors, Curr Gene Ther 5(3):323-31.
- 20 Taylor N, Uribe L, Smith S, Jahn T, Kohn D B, Weinberg K (1996), Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene, Blood 87(8):3103-7.
- 21 Oh Y K, Sohn T, Park J S, Kang M J, Choi H G, Kim J A, et al (2004), Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant, Virology 328(2):266-73.
- 22 Williams D A (2007), RAC reviews serious adverse event associated with AAV therapy trial, Mol Ther 15(12):2053-4.
- 23 Raposo G, Nijman H W, Stoorvogel W, Liejendekker R, Harding C V, Melief D J Geuze H J (1996), B lymphocytes secrete antigen-presenting vesicles, J Exp Med 183:1161-1172.
- 24 Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998), Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat Med 4:594-600.
- 25 Hao S, Moyana T, Xiang J (2007), Review: cancer immunotherapy by exosome-based vaccines, Cancer Biother Radiopharm 22:692-703.
- 26 Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J J, Lötvall J O (2007), Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol 9(6):654-9.
- 27 Skog J, Würdinger T, van Rijn S, Meijer D H, Gainche L, Sena-Esteves M, Curry W T Jr, Carter B S, Krichevsky A M, Breakefield X O (2008), Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat Cell Biol 10(12):1470-6.
- 28 Quah B J, O'Neill H C (2005), The immunogenicity of dendritic cell-derived exosomes, Blood Cells Mol Dis 35:94-110.
- 29 Théry C, Zitvogel L, Amigorena S (2002), Exosomes: composition, biogenesis and function, Nat Rev Immunol 2(8):569-79.
- 30 Jooss K, Yang Y, Fisher K J, Wilson J M (1998), Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers, J Virol 72(5):4212-23.
- 31 Reis e Sousa C (2006), Dendritic cells in a mature age, Nat Rev Immunol 6(6):476-83.
- 32 Kumar P, Wu H, McBride J L, Jung K E, Kim M H, Davidson B L, Lee S K, Shankar P, Manjunath N (2007), Transvascular delivery of small interfering RNA to the central nervous system, Nature 448(7149):39-43.
- 33 Flint P W, Li Z B, Lehar M, Saito K, Pai S I (2005), Laryngeal muscle surface receptors identified using random phage library, Laryngoscope 115(11):1930-7.
- Rippe K, Mücke N, Langowski J (1997), Superhelix dimensions of a 1868 base pair plasmid determined by scanning force microscopy in air and in aqueous solution, Nucleic Acids Res 25(9):1736-44.
- 35 Vijayanathan V, Thomas T, Shirahata A, Thomas T J (2001), DNA condensation by polyamines: a laser light scattering study of structural effects, Biochemistry 40(45):13644-51.
- 36 Lentz, T. L. Rabies virus binding to an acetylcholine receptor alpha-subunit peptide (1990). J. Mol. Recognit. 3, 82-88.
- 37 Zeng J, Too H P, Ma Y, Luo ESE, Wang S. A synthetic
peptide containing loop 4 of nerve growth factor for targeted gene delivery (2004). J Gene Med.; 6:1247-1256. - 38 McKay T, Reynolds P, Jezzard S, Curiel D, Coutelle C. Secretin-mediated gene delivery, a specific targeting mechanism with potential for treatment of biliary and pancreatic disease in cystic fibrosis (2002). Mol Ther; 5:447-454.
- 39 C. Théry, S. Amigorena, G. Raposo, A. Clayton, Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Ed. (Wiley, New York, April 2006)
Chapter 3, Unit 3.22 (2006). - 40 V. R. Simhadri, K. S. Reiners, H. P. Hansen, D. Topolar, V. L. Simhadri et al., Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One. 3(10), e3377 (2008), doi:10.1371/journal.pone.0003377.
- 41 Y. C. Wang, X. B. Hu, F. He, F. Feng, L. Wang et al., Lipopolysaccharide-induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J Biol Chem. 284(23), 15993-6003 (2009).
- 42 S. D. Larson, L. N. Jackson, L. A. Chen, P. G. Rychahou, B. M. Evers, Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery. 142(2):262-9 (2007).
- 43 H. Yin, H. M. Moulton, C. Betts, Y. Seow, J. Boutilier et al., A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet. 18(22):4405-14 (2009).
- 44 F. A. Nunes, E. E. Furth, J. M. Wilson, S. E. Raper, Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther. 10(15), 2515-26 (1999).
- S. C. Gonzalez, M. M. McMenamin, H M Charlton, J. Goodman, T Lantos, Readministration of adenoviral gene delivery to dopamine neurons. Neuroreport. 18(15), 1609-14 (2007).
- 46 F. M. Laird, H. Cai, A. V. Savonenko A. V. M. H. Farah, K. He et al., BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25(50), 11693-11709 (2005).
- 47 O. Singer, R. A. Man, E. Rockenstein, L. Crews, N. G. Coufal et al., Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8(10), 1343-1349 (2005).
- 48 K. Nishitomi, G. Sakaguchi, Y. Horikoshi, A. J. Gray, M. Maeda et al., BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 99(6), 1555-63 (2006).
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/548,995 US20220098589A1 (en) | 2009-04-17 | 2021-12-13 | Composition for delivery of genetic material |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0906693A GB0906693D0 (en) | 2009-04-17 | 2009-04-17 | Composition and method |
GB0906693.7 | 2009-04-17 | ||
GB0906692.9 | 2009-04-17 | ||
GB0906692A GB0906692D0 (en) | 2009-04-17 | 2009-04-17 | Composition |
PCT/GB2010/000762 WO2010119256A1 (en) | 2009-04-17 | 2010-04-15 | Composition for delivery of genetic material |
US201113264485A | 2011-12-16 | 2011-12-16 | |
US14/847,853 US10233445B2 (en) | 2009-04-17 | 2015-09-08 | Composition for delivery of genetic material |
US16/264,257 US10704047B2 (en) | 2009-04-17 | 2019-01-31 | Composition for delivery of genetic material |
US16/857,803 US11230715B2 (en) | 2009-04-17 | 2020-04-24 | Composition for delivery of genetic material |
US17/548,995 US20220098589A1 (en) | 2009-04-17 | 2021-12-13 | Composition for delivery of genetic material |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/857,803 Division US11230715B2 (en) | 2009-04-17 | 2020-04-24 | Composition for delivery of genetic material |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220098589A1 true US20220098589A1 (en) | 2022-03-31 |
Family
ID=42333482
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/264,485 Abandoned US20130053426A1 (en) | 2009-04-17 | 2010-04-15 | Composition For Delivery Of Genetic Material |
US14/847,853 Active US10233445B2 (en) | 2009-04-17 | 2015-09-08 | Composition for delivery of genetic material |
US15/364,794 Active US10329561B2 (en) | 2009-04-17 | 2016-11-30 | Composition for delivery of genetic material |
US16/264,257 Active US10704047B2 (en) | 2009-04-17 | 2019-01-31 | Composition for delivery of genetic material |
US16/857,803 Active US11230715B2 (en) | 2009-04-17 | 2020-04-24 | Composition for delivery of genetic material |
US17/548,995 Pending US20220098589A1 (en) | 2009-04-17 | 2021-12-13 | Composition for delivery of genetic material |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/264,485 Abandoned US20130053426A1 (en) | 2009-04-17 | 2010-04-15 | Composition For Delivery Of Genetic Material |
US14/847,853 Active US10233445B2 (en) | 2009-04-17 | 2015-09-08 | Composition for delivery of genetic material |
US15/364,794 Active US10329561B2 (en) | 2009-04-17 | 2016-11-30 | Composition for delivery of genetic material |
US16/264,257 Active US10704047B2 (en) | 2009-04-17 | 2019-01-31 | Composition for delivery of genetic material |
US16/857,803 Active US11230715B2 (en) | 2009-04-17 | 2020-04-24 | Composition for delivery of genetic material |
Country Status (8)
Country | Link |
---|---|
US (6) | US20130053426A1 (en) |
EP (3) | EP4122498A1 (en) |
JP (1) | JP5713325B2 (en) |
CN (1) | CN102497887A (en) |
DK (1) | DK2419144T3 (en) |
ES (2) | ES2927225T3 (en) |
PT (1) | PT2419144T (en) |
WO (1) | WO2010119256A1 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
JP5713325B2 (en) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | Composition for delivery of genetic material |
PL3338765T3 (en) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Steroid derivative for the delivery of mrna in human genetic diseases |
WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
WO2012091136A1 (en) * | 2010-12-28 | 2012-07-05 | 学校法人東京医科大学 | Expression vector, method for producing carrier using same, and use of same |
WO2012162563A2 (en) | 2011-05-24 | 2012-11-29 | The Regents Of The University Of California | Method for exosomal biomarker detection by electric field-induced release and measurement |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
WO2013090523A2 (en) * | 2011-12-13 | 2013-06-20 | Henry Ford Health System | Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery |
US10227593B2 (en) | 2011-12-13 | 2019-03-12 | Henry Ford Health System | Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery |
KR101993027B1 (en) * | 2012-04-03 | 2019-09-30 | 레뉴런 리미티드 | Stem cell microparticles |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Nuclease resistant polynucleotides and uses thereof |
JP6272765B2 (en) * | 2012-10-01 | 2018-01-31 | 国立大学法人京都大学 | Nanogel / exosome complex and DDS |
CN103865942A (en) * | 2012-12-18 | 2014-06-18 | 常州碳宇纳米科技有限公司 | Nano-particles capable of improving gene transfection efficiency and preparation method of gene transfection reagent based on particles |
US10308959B2 (en) | 2013-01-18 | 2019-06-04 | Henry Ford Health System | Methods, systems, and compositions relating to MiRNA-146a |
PL2972193T3 (en) | 2013-03-13 | 2020-08-24 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
PT2968586T (en) | 2013-03-14 | 2018-11-13 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
JP6137894B2 (en) * | 2013-03-22 | 2017-05-31 | 国立大学法人京都大学 | Liposome-exosome hybrid vesicle and preparation method thereof |
CA2910802A1 (en) * | 2013-04-12 | 2014-10-16 | Samir El Andaloussi | Therapeutic delivery vesicles |
US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
CN104726410B (en) * | 2013-12-23 | 2019-09-17 | 浙江大学 | A kind of efflux body and its application with immune suppression function |
AU2015208837B2 (en) | 2014-01-21 | 2020-06-18 | Anjarium Biosciences Ag | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
EP3132044B1 (en) | 2014-04-18 | 2020-04-08 | University of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
WO2016013660A1 (en) * | 2014-07-24 | 2016-01-28 | 凸版印刷株式会社 | Lipid membrane structure, lipid-membrane-structure-immobilization carrier, and method for fusing cells |
CA2962081A1 (en) * | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes useful to treat lysosomal storage disease |
WO2016115632A1 (en) * | 2015-01-21 | 2016-07-28 | Exerkine Corporation | Method for treating mitochondrial disease |
KR20160130937A (en) * | 2015-05-04 | 2016-11-15 | 한국과학기술원 | Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby |
WO2016179417A2 (en) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Exosome delivery of micrornas |
BR112017026467A2 (en) | 2015-06-10 | 2018-09-11 | Univ Texas | use of exosomes to treat disease |
WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
US9840542B2 (en) * | 2015-09-11 | 2017-12-12 | Nomadogen Biotechnologies Inc. | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells |
US10624849B2 (en) * | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
SG11201804117XA (en) | 2015-11-18 | 2018-06-28 | Univ Georgia | Neural cell extracellular vessicles |
WO2017147720A1 (en) * | 2016-03-04 | 2017-09-08 | Exerkine Corporation | Method for treating a central nervous system disorder |
US20190112351A1 (en) * | 2016-04-04 | 2019-04-18 | National Institutes Of Biomedical Innovation, Health And Nutrition | Exosome-targeted dna vaccine |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
CA3036093A1 (en) * | 2016-09-09 | 2018-03-15 | Cornell University | Delivery of nucleic acids, proteins, and small molecules in vitreous vesicular bodies |
WO2018089901A2 (en) | 2016-11-14 | 2018-05-17 | Joslin Diabetes Center | Exosome delivery system |
US20200069594A1 (en) * | 2016-12-09 | 2020-03-05 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
WO2018187957A1 (en) * | 2017-04-12 | 2018-10-18 | Shenzhen International Institute For Biomedical Research | Pum 1 protein as target for virus inhibition |
EP3624824A1 (en) | 2017-05-16 | 2020-03-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
US11674130B2 (en) * | 2017-08-04 | 2023-06-13 | Ohio State Innovation Foundation | Method for producing therapeutic exosomes from nanoelectroporation and other non-endocytic cell transfection |
CA3073162C (en) * | 2017-08-17 | 2023-07-04 | Ilias Biologics Inc. | Exosomes for target specific delivery and methods for preparing and delivering the same |
AU2018333072B2 (en) | 2017-09-18 | 2022-09-29 | Cz Biohub Sf, Llc | Methods for treating triple-negative breast cancer |
WO2019067587A1 (en) | 2017-09-26 | 2019-04-04 | University Of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders |
GB2568255A (en) | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
US11766402B2 (en) | 2017-11-16 | 2023-09-26 | Board Of Regents, The University Of Texas System | Methods for production of MSC-derived exosomes |
CA3082588A1 (en) * | 2017-11-17 | 2019-05-23 | Codiak Biosciences, Inc. | Compositions of engineered exosomes and methods of loading luminal exosome payloads |
US20190153409A1 (en) * | 2017-11-17 | 2019-05-23 | Aviv MedTech Ltd. | Compositions comprising particles and methods for treating cancer |
US10723782B2 (en) * | 2017-12-28 | 2020-07-28 | Codiak Biosciences, Inc. | Exosomes for immuno-oncology and anti-inflammatory therapy |
JP7416433B2 (en) * | 2018-04-10 | 2024-01-17 | ノースウェスタン ユニバーシティ | Extracellular vesicles containing membrane proteins based on targeting affinity domains |
JP2021528096A (en) * | 2018-06-28 | 2021-10-21 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Exosome extracellular vesicles and how to use them |
WO2020030561A1 (en) | 2018-08-10 | 2020-02-13 | Unicyte Ev Ag | Extracellular vesicles loaded with an exogenous molecule |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3620519A1 (en) * | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
WO2020154210A1 (en) * | 2019-01-22 | 2020-07-30 | Research Institute At Nationwide Children's Hospital | Methods for detecting and treating hepatic cancers |
WO2020154746A1 (en) * | 2019-01-25 | 2020-07-30 | Mantra Bio, Inc. | Skeletal muscle targeting moieties and uses thereof |
CN109701038B (en) * | 2019-02-22 | 2021-02-23 | 上海大学 | Brain targeting exosome, preparation method and application thereof |
GB201906482D0 (en) | 2019-05-08 | 2019-06-19 | Evox Therapeutics Ltd | Exosome comprising stabilized RNA therapeutics |
EP4034550A4 (en) * | 2019-09-23 | 2023-09-27 | University of Florida Research Foundation, Incorporated | Vaccine therapy for ran protein diseases |
CN112972702A (en) * | 2019-12-17 | 2021-06-18 | 南京大学 | Exosome preparation for treating drug-resistant bacterial infection |
CN115151277A (en) * | 2020-01-13 | 2022-10-04 | 胭脂红治疗私人有限公司 | Erythrocyte outer vesicle loaded with nucleic acid |
WO2021205459A1 (en) | 2020-04-07 | 2021-10-14 | Ramot At Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
WO2022040516A1 (en) | 2020-08-21 | 2022-02-24 | University Of Miami | Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells |
WO2022198187A1 (en) * | 2021-03-15 | 2022-09-22 | Ohio State Innovation Foundation | Extracellular vesicle-based nanocarriers |
IT202100007304A1 (en) * | 2021-03-25 | 2022-09-25 | Exo Lab Italia | METHOD OF APPLICATION OF ELECTRIC IMPULSES FOR THE PURPOSE OF LOADING MOLECULES OF VARIOUS NATURES INTO NANOVESICLES OF VEGETABLE ORIGIN |
WO2023102550A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
WO2023183860A1 (en) * | 2022-03-23 | 2023-09-28 | University Of Delaware | Engineered extracellular vesicles for targeted drug delivery to muscle |
WO2023205158A1 (en) | 2022-04-19 | 2023-10-26 | University Of Miami | Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4203413C2 (en) | 1992-02-06 | 1993-11-25 | Fraunhofer Ges Forschung | Multiple scanning method |
US5166646A (en) | 1992-02-07 | 1992-11-24 | Motorola, Inc. | Integrated tunable resonators for use in oscillators and filters |
CA2225553A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
US6669835B1 (en) | 1997-02-18 | 2003-12-30 | Atofina Chemicals, Inc. | Aqueous dispersions of polymerizable reactants and a water incompatible catalyst sorbed on an inorganic particulate carrier |
FR2766205B1 (en) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
FR2785543B1 (en) | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | MODIFIED EXOSOMES AND USES |
US6627421B1 (en) | 1999-04-13 | 2003-09-30 | Imarx Therapeutics, Inc. | Methods and systems for applying multi-mode energy to biological samples |
GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
FR2812813B1 (en) * | 2000-08-09 | 2004-11-26 | Neovacs | USE OF IMMUNOGENS TO TREAT OR PREVENT WITHIN MALIGNANT TUMORS IMMUNE DISORDERS INDUCED BY EXTRACELLULAR FACTORS |
US7704964B2 (en) | 2001-08-17 | 2010-04-27 | Exothera L.L.C. | Methods and compounds for the targeting of protein to exosomes |
KR100519384B1 (en) | 2002-08-13 | 2005-10-06 | (주)누백스 | Manufacturing method of exosomes using gene transfection and use of the same |
JP4939926B2 (en) * | 2003-02-14 | 2012-05-30 | アノシス・インコーポレーテッド | Methods and compounds for generating antibodies and screening antibody repertoires |
JP2006518219A (en) | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | Method of loading antigen to cells by electroporation |
US20050153304A1 (en) | 2003-04-10 | 2005-07-14 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Multivariate profiling of complex biological regulatory pathways |
EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
CN1322115C (en) * | 2005-07-06 | 2007-06-20 | 清华大学 | Ectobody loaded with exogenous ligand molecule and its preparation method and application |
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
WO2008052205A2 (en) * | 2006-10-27 | 2008-05-02 | Jumptap, Inc. | Combined algorithmic and editorial-reviewed mobile content search results |
US8455188B2 (en) | 2007-01-26 | 2013-06-04 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
JP2011524164A (en) | 2008-06-06 | 2011-09-01 | サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク(セー・エヌ・エール・エス) | Use of endolysosomal systems and secretory vesicles (exosome-like) in small RNA based therapeutics and diagnostics and experimental studies of small RNAs |
JP5713325B2 (en) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | Composition for delivery of genetic material |
WO2010141716A2 (en) | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for diagnosing light chain amyloidosis |
EP2270969B8 (en) | 2009-07-02 | 2012-04-11 | Converteam Technology Ltd | Control methods for parallel-connected power converters |
CA2766833A1 (en) | 2009-07-02 | 2011-01-06 | Ith Immune Therapy Holdings Ab | Exosome-based treatment of cancer |
WO2011011733A2 (en) | 2009-07-24 | 2011-01-27 | The Regents Of The University Of Michigan | Factor replacement therapy |
GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
WO2014106604A1 (en) | 2013-01-03 | 2014-07-10 | Unilever Plc | Hair care composition |
-
2010
- 2010-04-15 JP JP2012505223A patent/JP5713325B2/en active Active
- 2010-04-15 EP EP22178389.7A patent/EP4122498A1/en active Pending
- 2010-04-15 ES ES19178842T patent/ES2927225T3/en active Active
- 2010-04-15 CN CN2010800268640A patent/CN102497887A/en active Pending
- 2010-04-15 EP EP10714058.4A patent/EP2419144B1/en active Active
- 2010-04-15 ES ES10714058T patent/ES2749393T3/en active Active
- 2010-04-15 DK DK10714058.4T patent/DK2419144T3/en active
- 2010-04-15 EP EP19178842.1A patent/EP3569254B1/en active Active
- 2010-04-15 PT PT10714058T patent/PT2419144T/en unknown
- 2010-04-15 US US13/264,485 patent/US20130053426A1/en not_active Abandoned
- 2010-04-15 WO PCT/GB2010/000762 patent/WO2010119256A1/en active Application Filing
-
2015
- 2015-09-08 US US14/847,853 patent/US10233445B2/en active Active
-
2016
- 2016-11-30 US US15/364,794 patent/US10329561B2/en active Active
-
2019
- 2019-01-31 US US16/264,257 patent/US10704047B2/en active Active
-
2020
- 2020-04-24 US US16/857,803 patent/US11230715B2/en active Active
-
2021
- 2021-12-13 US US17/548,995 patent/US20220098589A1/en active Pending
Non-Patent Citations (3)
Title |
---|
Flint et al , Laryngeal Muscle Surface Receptors Identified using Random Phage Library, The Laryngoscope, 2005, 115: 1930-1937 (Year: 2005) * |
Lentz , Rabies Virus Binding to an Acetylcholine Receptor a-Subunit Peptide, Journal of Molecular recognition, 1990, vol.3, no.2: 82-88 (Year: 1990) * |
Ruffner et al , Delaying the Onset of Diabetes in the NOD Mouse Using Exosomes Derived from Dendritic Cells Transfected with Adenoviral Vectors, Molecular Therapy, 2006, vol.13, suppl.1, Abstract 566, page S218 (Year: 2006) * |
Also Published As
Publication number | Publication date |
---|---|
US10329561B2 (en) | 2019-06-25 |
US10704047B2 (en) | 2020-07-07 |
PT2419144T (en) | 2019-09-16 |
WO2010119256A1 (en) | 2010-10-21 |
US20190153445A1 (en) | 2019-05-23 |
US20200308587A1 (en) | 2020-10-01 |
EP4122498A1 (en) | 2023-01-25 |
DK2419144T3 (en) | 2019-10-21 |
ES2927225T3 (en) | 2022-11-03 |
US20170182182A1 (en) | 2017-06-29 |
US11230715B2 (en) | 2022-01-25 |
EP2419144A1 (en) | 2012-02-22 |
JP2012524052A (en) | 2012-10-11 |
EP3569254B1 (en) | 2022-07-20 |
US10233445B2 (en) | 2019-03-19 |
EP2419144B1 (en) | 2019-08-07 |
ES2749393T3 (en) | 2020-03-20 |
US20130053426A1 (en) | 2013-02-28 |
EP3569254A1 (en) | 2019-11-20 |
US20160067355A1 (en) | 2016-03-10 |
JP5713325B2 (en) | 2015-05-07 |
CN102497887A (en) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11230715B2 (en) | Composition for delivery of genetic material | |
US20140348904A1 (en) | Exosomes With Transferrin Peptides | |
US9526799B2 (en) | Low density lipoprotein receptor-mediated siRNA delivery | |
Singh et al. | Subcellular fate and off-target effects of siRNA, shRNA, and miRNA | |
US20070281900A1 (en) | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY | |
US20080076701A1 (en) | Dicer substrate rna peptide conjugates and methods for rna therapeutics | |
Peer | A daunting task: manipulating leukocyte function with RNA i | |
US9932584B2 (en) | Interfering RNA delivery system and uses thereof | |
Lindberg et al. | Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides | |
WO2022165262A1 (en) | Compositions and methods for delivering cargo to a target cell | |
Rivera et al. | Critical issues in delivery of RNAi therapeutics in vivo | |
Yuan et al. | RNA Therapeutics in Targeting G Protein-Coupled Receptors: Recent Advances and Challenges | |
Shim et al. | 7 Targeted Delivery Systems of Nonviral Nucleic Acid–Based Therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OXFORD UNIVERSITY INNOVATION LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:ISIS INNOVATION LIMITED;REEL/FRAME:058496/0451 Effective date: 20160616 Owner name: ISIS INNOVATION LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEOW, YIQI;ALVAREZ, LYDIA;WOOD, MATTHEW;SIGNING DATES FROM 20111121 TO 20111128;REEL/FRAME:058379/0001 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |